%PDF-1.3 %âãÏÓ 2 0 obj <> endobj 5 0 obj <>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 53/FormType 1/Filter/FlateDecode>>stream xœs áÒw3T04PIã2P0TÐ5T0q-ÍBr¹44C²¸@B 9 s á(P ’ endstream endobj 3 0 obj <>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 54/FormType 1/Filter/FlateDecode>>stream xœs áÒw3T04PIã2P0TÐ5TR Æ–f !¹\š!Y\ !ˆŠ¹†p)P š endstream endobj 1 0 obj <>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 53/FormType 1/Filter/FlateDecode>>stream xœs áÒw3T04PIã2P0TÐ5T0q-ÍBr¹44C²¸@B 9 s á(P ’ endstream endobj 6 0 obj <>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 54/FormType 1/Filter/FlateDecode>>stream xœs áÒw3T04PIã2P0TÐ5TR Æ–f !¹\š!Y\ !ˆŠ¹†p)P š endstream endobj 8 0 obj <>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 53/FormType 1/Filter/FlateDecode>>stream xœs áÒw3T04PIã2P0TÐ5T0q-ÍBr¹44C²¸@B 9 s á(P ’ endstream endobj 4 0 obj <>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 55/FormType 1/Filter/FlateDecode>>stream xœs áÒw3T04PIã2P0TÐ5T0P02S0¶4SÉåÒÐÉâ ä@$PÌ5„)1 ™ endstream endobj 10 0 obj <>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 55/FormType 1/Filter/FlateDecode>>stream xœs áÒw3T04PIã2P0TÐ5T0P02S0¶4SÉåÒÐÉâ ä@$PÌ5„)1 ™ endstream endobj 7 0 obj <>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 55/FormType 1/Filter/FlateDecode>>stream xœs áÒw3T04PIã2P0TÐ5T0P02S0¶4SÉåÒÐÉâ ä@$PÌ5„)1 ™ endstream endobj 9 0 obj <>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 54/FormType 1/Filter/FlateDecode>>stream xœs áÒw3T04PIã2P0TÐ5TR Æ–f !¹\š!Y\ !ˆŠ¹†p)P š endstream endobj 11 0 obj <>stream 2012-09-20T12:25:39+05:30 Arbortext Advanced Print Publisher 9.0.114/W 2012-09-26T06:50:58-07:00 Acrobat Distiller 8.1.0 (Windows) application/pdf untitled uuid:5890b57e-09a7-49d4-b8cc-6320af3938d7 uuid:3e5161b2-9621-4c0f-9bbf-a0dbf1d225ea endstream endobj 12 0 obj <>stream xœ+äî| endstream endobj 13 0 obj <>stream xœSä*ä*T0T0B™œ« ‘i¦à’¯ˆUÊ·”D*:šÚ endstream endobj 14 0 obj <>stream xœ+äî| endstream endobj 15 0 obj <>stream xœSä*ä*T0T0B™œ« ‘i à’¯ˆUÊ·”D*8È endstream endobj 16 0 obj <>stream xœ+äî| endstream endobj 17 0 obj <>stream xœSä*ä*T0T0B™œ« ‘i¬à’¯ˆUÊ·”)D*9VÑ endstream endobj 18 0 obj <>/XObject<>/ProcSet [/PDF /Text /ImageB /ImageC /ImageI]/Font<>>>/Thumb 26 0 R/MediaBox[0 0 612 792]/Rotate 0>> endobj 27 0 obj <>/ProcSet[/PDF/Text]/Font<>>> endobj 20 0 obj <>stream /GS1 gs BT /F4 1 Tf 8.9663 0 0 8.9663 62.022 725.7825 Tm 0 0 0 1 k 0 Tc 0 Tw [(protein)-233.4(oxidation)-236.1(and)-233.5(human)-232.8(disease)-236.1(are)-227.7(widely)-237.3(appreciated,)]TJ 0 -1.2203 TD [(although)-455.1(unraveling)-450.4(cause)-450.3(and)-448.5(effect)-455.7(remains)-448.5(a)-448.4(challenge.)]TJ 0 -1.2266 TD [(Increasing)-460.2(biomedical)-459.7(data)-451.4(have)-458.8(provided)-457.6(compelling)-461.9(evi-)]TJ 0 -1.2203 TD [(dences)-392.5(for)-389.6(the)-395.8(involvement)-389(of)-395.3(redox)-387.9(homeostasis)-393.2(perturba-)]TJ T* [(tions)-504.7(in)-500.1(a)-499(large)-501.2(number)-500.5(of)-496.4(pathophysiological)-508.8(conditions,)]TJ 0 -1.2266 TD [(including)-474.4(type)-480.4(2)-467.4(diabetes)-479.9(mellitus,)-475.7(cardiovascular)-476.3(disease,)]TJ 0 -1.2203 TD [(atherosclerosis,)-535.5(stroke,)-537.3(many)-529.7(types)-532.3(of)-534.4(cancer,)-529.8(and)-530.7(neuro-)]TJ T* [(degenerative)-635(diseases)-629.4(such)-631.3(as)-626.8(AlzheimerÕs)-632.3(disease,)-631(mild)]TJ 0 -1.2266 TD [(cognitive)-669.3(impairment,)-668(amyotrophic)-673.4(lateral)-664.7(sclerosis,)-667.8(and)]TJ 0 -1.2203 TD [(ParkinsonÕs)-320.8(disease)-324.6($1,)-319(6$.)-319(Oxidative/nitrosative)-326.1(stressÑand)]TJ T* [(the)-288.3(resulting)-284.2(damage)-282.1(to)-287.8(the)-282(major)-283.7(classes)-290.7(of)-281.5(macromolecules)]TJ T* [(in)-430.6(cells,)-434.1(mainly)-429.3(to)-433.2(proteins)-430.7(and)-435.9(lipidsÑis)-431.1(also)-430.8(involved)-434.9(in)]TJ 0 -1.2266 TD [(physiological)-311.6(aging)-312.4(and)-309.4(degenerative)-318.9(processes)-311.3(occurring)-318.9(in)]TJ 0 -1.2203 TD [(age-related)-371.7(diseases)-376.5($1Ð9$.)-369.1(However,)-368.9(deÞnitive)-377.9(evidence)-370(for)]TJ T* [(the)-263(link)-255.1(between)-262.5(oxidative)-262.2(damage)-256.8(and)-258.8(either)-260.8(the)-256.7(primary)-260.7(or)]TJ 0 -1.2266 TD [(secondary)-311.5(pathophysiological)-312.8(mechanisms)-303.9(of)-306.7(multiple)-308.4(acute)]TJ 0 -1.2203 TD [(and)-201.9(chronic)-208.4(human)-201.2(diseases)-205.8(has)-206.5(often)-203(been)-203.6(lacking)-201.4(because)-208(of)]TJ T* [(recognized)-452.7(shortcomings)-457.2(with)-451.6(methods)-457.3(available)-450.5(to)-452.2(assess)]TJ 0 -1.2266 TD [(oxidative)-445.6(stress)-447.6(status)-447(and)-448.5(the)-446.4(resulting)-448.6(oxidative)-445.6(damage)]TJ /F5 1 Tf 0 -1.2203 TD [(in)-278.2(vivo)]TJ /F4 1 Tf 3.0919 0 TD [(in)-278.8(humans.)]TJ -1.9791 -1.2203 TD [(In)-460.8(the)-459(last)-460.1(few)-463.6(years,)-457.7(combined)-462.8(proteomics,)-467.8(mass)-455(spec-)]TJ -1.1128 -1.2203 TD [(trometry)-386.4($)-82.7(MS$,)-380(and)-385.3(afÞnity)-381.5(chemistry-based)-385.9(methodologies)]TJ 0 -1.2266 TD [(have)-294.4(contributed)-291.2(in)-291.4(a)-290.4(signiÞcant)-287.4(way)-290.1(to)-294.1(provide)-290.2(a)-290.4(better)-290.4(un-)]TJ 0 -1.2203 TD [(derstanding)-383(of)-376.3(protein)-385.2(oxidative)-382.3(modiÞcations)-380.6(occurring)-382.2(in)]TJ T* [(various)-484.1(biological)-482.6(specimens)-481.8(under)-482.6(different)-486(physiological)]TJ 0 -1.2266 TD [(and)-473.8(pathological)-485.7(conditions)-478.7($)]TJ /F5 1 Tf 13.4046 0 TD (e.g.)Tj /F4 1 Tf 1.3847 0 TD [(,)-477.1(1Ð9$.)-476.1(Indeed,)-475.8(redox)-476.4(pro-)]TJ -14.7893 -1.2203 TD [(teomics)-523.3(results)-520.7(obtained)-522.8(in)-519.1(different)-524(human)-517.4(diseases)-521.9(and)]TJ T* [(animal)-456(models)-457(thereof)-462.8(may)-456.7(provide)-460.9(new)-453.8(insights)-464(into)-459.1(the)]TJ 0 -1.2266 TD [(main)-528.8(mechanisms)-531.6(involved)-536.1(in)-531.7(the)-528.6(pathogenesis)-533.4(and)-530.7(pro-)]TJ 0 -1.2203 TD [(gression)-384.1(of)-382.6(oxidative)-388.7(stress-related)-385.5(diseases,)-385.8(such)-384.7(as)-380.2(neuro-)]TJ T* [(degenerative)-287.2(disorders)-281.8(and)-277.8(cardiovascular)-286.6(disease.)]TJ 1.1128 -1.2266 TD [(The)-303.5(study)-307.7(of)-306.7(the)-300.9(role)-310.4(of)-306.7(ROS/RNS)-302.3(and)-309.4(oxidative)-306.5(stress)-308.5(in)]TJ -1.1128 -1.2203 TD [(disease)-217.1(and)-208.2(aging)-211.3(involves)-218.3(the)-212.4(measurement)-216.5(of)-211.9(biomarkers)-217.2(of)]TJ T* [(oxidative)-230.6(damage)-225.2(that)-225.1(reßect)-224.6(damage)-225.2(induced)-228.4(from)-229.1(an)-224.2(attack)]TJ T* [(by)-299.7(speciÞc)-298.5(ROS/RNS)-302.3(or)-294.3(secondary)-298.8(by-products)-304.1(of)-300.4(oxidative)]TJ 0 -1.2266 TD [(stress.)-355.7(In)-353.3(fact,)-356.7(although)-354(some)-355.6(ROS/RNS)-352.9(can)-356.3(be)-352.1(directly)-356.3(de-)]TJ 0 -1.2203 TD [(tected,)-379(currently)-380.5(available)-380.9(methods)-381.5(are)-379.5(not)-379.7(generally)-379.7(appli-)]TJ T* [(cable)-234.3(to)-230.9(clinical)-236.9(examination)-237(due)-231.9(to)-230.9(the)-237.7(chemical)-233.6(instability)-236.8(of)]TJ 0 -1.2266 TD [(most)-400.5(ROS/RNS,)-400.1(which)-403.2(are)-398.5(too)-398(reactive)-402.4(and/or)-398.1(have)-395.6(a)-397.9(too)]TJ 0 -1.2203 TD [(short)-211(half-life.)-213.7(Therefore,)-209.7(such)-214(molecules)-211.5(cannot)-211.1(be)-206.6(isolated)-210(or)]TJ T* [(measured)-382.6(directly)-381.6(in)-380(cells,)-383.5(tissues,)-378.8(and)-379(body)-381.3(ßuids.)-381.9(In)-378.5(con-)]TJ 0 -1.2266 TD [(trast,)-327.9(molecular)-324.3(products)-326.4(formed)-320.6(from)-324(the)-326.2(reaction)-325.7(of)-325.7(ROS/)]TJ 0 -1.2203 TD [(RNS)-489.6(with)-489.6(various)-484.1(biomolecules)-494.1(are)-487(generally)-487.2(more)-487.8(stable)]TJ T* [(than)-259.7(ROS/RNS)-258(themselves.)-263.9(As)-255.6(a)-252.4(consequence,)-264.4(in)-259.8(most)-255(cases,)]TJ T* [(production)-777.4(of)-774.6(ROS/RNS)-770.2(has)-775.6(commonly)-776.4(been)-772.7(inferred)]TJ 0 -1.2266 TD [(by)-343.9(measuring)-353.1(stable)-344.3(metabolites)-354.8(and/or)-347.5(their)-349.4(oxidation)-343.6(tar-)]TJ 0 -1.2203 TD [(get)-586.5(products,)-588.6(including)-588.2(stable)-590.9(markers)-585.8(of)-585(oxidative)-591(pro-)]TJ T* [(tein)-456.2(damage)-452.8(such)-454.3(as)-456.1(nitrotyrosine,)-460.2(dityrosine,)-455.9(and)-454.8(protein)]TJ 0 -1.2267 TD [(carbonyls)-284.9($1Ð9$.)]TJ 1.1128 -1.2203 TD [(Research)-343.3(toward)-343.2(a)-340.9(better)-347.3(understanding)-349.8(of)-344.7(the)-338.9(molecular)]TJ -1.1128 -1.2203 TD [(mechanisms)-335.6(of)-325.7(a)-328.3(disease)-330.9(together)-334.5(with)-331.5(identiÞcation)-335.6(of)-332(spe-)]TJ 0 -1.2266 TD [(ciÞc)-371.8(targets)-367.2(of)-370(oxidative)-369.7(damage)-370.6(is)-365.2(urgently)-372.3(required.)-370.5(Con-)]TJ 0 -1.2203 TD [(currently,)-301.2(there)-301.5(is)-302(an)-300.1(overwhelming,)-302.6(urgent)-301.1(need)-303.4(to)-300.4(validate)]TJ T* [(more)-234.9(speciÞc)-241.6(oxidative)-236.9(damage)-237.9(biomarkers)-236.1(that)-237.8(can)-236.1(be)-231.9(easily)]TJ 0 -1.2266 TD [(measured)-224.5(in)-228.2(human)-226.5(biological)-223.3(ßuids,)-230.1(to)-224.5(overcome)-224.9(limitations)]TJ 0 -1.2203 TD [(of)-313.1(invasive)-316.2(monitoring)-313.4($1,)-312.7(6$.)-306.4(A)-311.2(few)-318.1(biomarkers)-312(of)-313.1(oxidative)]TJ T* [(stress/damage)-277.5(are)-272(validated)-278.8(and)-271.5(commonly)-276.9(used.)-274.1(However,)]TJ T* [(limited)-466.8(human)-466.8(data)-464.1(are)-461.7(available)-463.1(on)-467.7(the)-465.3(levels)-464.2(of)-464.8(speciÞc)]TJ 0 -1.2266 TD [(biomarkers)-356.3(of)-351(protein)-359.9(damage)-351.7(in)-348.4(controlled)-360.8(clinical)-350.7(studies.)]TJ 0 -1.2203 TD [(Consequently,)-451.6(at)-442.6(present,)-446.2(it)-446.6(is)-441.1(unknown)-450.3(if)-440.3(some)-450.5(oxidative)]TJ T* [(stress-induced)-474.2(protein)-467.4(modiÞcations)-475.4(may)-463.1(be)-465.9(an)-464.5(important)]TJ 0 -1.2267 TD [(tool)-414.2(in)-411.6(clinical)-413.9(trials)-413.7(as)-411.8(biomarkers)-413.2(of)-414.2(oxidative)-414(stress)-416(and,)]TJ 27.9978 74.5598 TD [(more)-462.5(importantly,)-463.2(may)-463.1(have)-458.8(diagnostic)-463.8($particularly)-461(early)]TJ 0 -1.2203 TD [(and)-277.8(possibly)-281.9(presymptomatic$)-282.6(and)-277.8(therapeutic)-281.7(uses.)-278.7(Current)]TJ 0 -1.2266 TD [(research)-346.1(progress)-341.3(on)-341.3(the)-345.2(detailed)-341.6(measurement)-343(of)-344.7(oxidative)]TJ 0 -1.2203 TD [(damage)-421.2(to)-420.6(proteins)-424.4(by)-419.8(different)-429.1(redox)-419.5(proteomics)-427(and)-416.9(MS)]TJ T* [(technologies)-334.5(suggests)-324.3(that)-326.3(many)-321(more)-323.4(biomarkers)-324.7(are)-322.6(likely)]TJ 0 -1.2266 TD [(to)-281.4(be)-282.5(developed)-286(and)-277.8(clearly)-282.8(validated)-285.1(in)-278.8(the)-282(near)-281.7(future.)]TJ 1.1128 -1.2203 TD [(In)-618.8(contrast)-621.2(to)-622.9(measurement)-621.2(of)-616.6(individual)-619.5(biomarkers,)]TJ -1.1128 -1.2203 TD [(proteomic)-526.8(analysis)-516(presents)-520.5(the)-522.2(opportunity)-522.1(to)-521.7(identify)-518.2(a)]TJ 0 -1.2266 TD [(panel)-349.1(of)-338.4(complementary)-345.5(biomarkers)-349.9(that)-339(can)-343.6(give)-343.7(extensive)]TJ 0 -1.2203 TD [(information)-201.5(regarding)-196.6(a)-195.5(disease)-198.2($1,)-198.9(6$.)-192.6(Such)-198.5(biomarkers)-198.2(can)-198.2(be)]TJ T* [(considered)-193.8(as)-190.5(a)-182.9(panel)-191.1(of)-186.6(up-)-192.9(and)-182.9(downregulated)-194.3(proteins)-190.5(with)]TJ T* [(altered)-367.4(post-translational)-369.5(modiÞcations,)-364.5(which)-365.3(differ)-368.5(in)-361(dis-)]TJ 0 -1.2266 TD [(ease)-417.9(and)-410.6(normal)-418.5(state.)-415.6(Of)-414.5(course,)-412.9(although)-417.2(it)-415(is)-415.8(likely)-411.3(that)]TJ 0 -1.2203 TD [(some)-494.7(future)-497.4(results)-495.4(may)-488.4(ultimately)-494.8(show)-496(that)-490.7(changes)-498.1(in)]TJ T* [(ROS/RNS)-485.7(concentration)-480.4(and)-480.1(oxidative)-477.2(protein)-480(damage)-478.1(in)]TJ 0 -1.2266 TD [(some)-203.9(situations)-207.3(are)-196.1(merely)-202(epiphenomena,)-208.6(it)-200(is)-200.9(also)-203.1(likely)-196.4(that)]TJ 0 -1.2203 TD [(future)-238.2(research)-238.6(development)-233.8(in)-234.5(redox)-236.2(proteomics)-237.3(will)-233.5(be)-231.9(able)]TJ T* [(to)-192.9(provide)-189(the)-193.4(biomedical)-187.8(research)-194.4(community)-187.4(with)-192.4(new)-188.3(tools)]TJ 0 -1.2266 TD [(to)-376.3(assess)-371.4(the)-376.8(signiÞcance)-374.6(of)-370(oxidative)-376(protein)-378.8(modiÞcations)]TJ 0 -1.2203 TD [(and,)-293.4(indirectly,)-290.2(of)-294.1(ROS/RNS,)-292.6(in)-291.5(biological)-292.9(systems.)-287.4(Progress)]TJ T* [(in)-335.7(the)-332.5(Þeld)-331.9(of)-332(redox)-331(proteomics)-332.1(should)-337.8(advance)-327.8(our)-333.6(knowl-)]TJ T* [(edge)-532(of)-534.4(regulatory)-529.9(mechanisms)-531.6(that)-535(involve)-526.8(oxidation)-533.3(of)]TJ 0 -1.2266 TD [(proteins,)-332.5(especially)-326.1(at)-322.5(cysteine)-328.3(residues,)-330.1(and)-322(lead)-322.1(to)-325.7(a)-322(better)]TJ 0 -1.2203 TD [(understanding)-400.4(of)-388.9(oxidative)-388.7(biochemistry)-394.3(in)-392.6(health)-389.6(and)-391.6(dis-)]TJ T* [(ease.)-414.5(Thus,)-410.3(redox)-413.2(proteomics)-414.3(promises)-413.1(a)-410.5(signiÞcant)-413.9(contri-)]TJ 0 -1.2266 TD [(bution)-578.7(in)-576(the)-579.1(Þeld)-578.5(of)-572.3(molecular)-577.2(biology)-576(and)-575(biomedical)]TJ 0 -1.2203 TD [(research,)-197.3(especially)-199.6(in)-190.3(the)-199.8(elucidation)-197.3(of)-192.9(redox-dependent)-200.3(and)]TJ T* [(ROS/RNS-dependent)-367.7(signaling)-362.1(mechanisms)-360.8(and)-353.7(in)-361(the)-357.8(dis-)]TJ 0 -1.2266 TD [(covery)-349.2(of)-338.4(diagnostic)-350(biomarkers)-343.6(enabling)-344.6(early)-336.9(diagnosis)-345.2(of)]TJ 0 -1.2203 TD [(various)-345(oxidative)-344.4(stress-related)-347.6(human)-346.6(diseases.)-341.5(We)-340.4(believe)]TJ T* [(that)-294.7(redox)-286.7(proteomics)-294.2(will)-290.4(contribute)-294.5(to)-287.8(broaden)-291.9(our)-289.4(knowl-)]TJ 0 -1.2266 TD [(edge)-392.9(concerning)-393.1(potential)-394.3(biomarkers)-394.2(for)-389.6(disease)-394.2(diagnosis)]TJ 0 -1.2203 TD [(and)-391.6(may)-393.5(also)-386.5(provide)-397.7(insight)-393.1(into)-389.5(damaged)-392.6(metabolic)-390.4(net-)]TJ T* [(works)-402.9(and)-397.9(potential)-400.6(targets)-405.1(for)-396(modulation)-403.6(of)-395.3(disease)-400.5(pro-)]TJ T* [(gression)-226(by)-223.8(means)-223(of)-224.6(drug)-224.4(therapy.)-221.3(Indeed,)-229.2(redox)-223.5(proteomics)]TJ 0 -1.2266 TD [(will)-360(plausibly)-351.8(play)-356.6(a)-353.6(pivotal)-353.4(role)-361(also)-354.9(in)-348.4(the)-357.8(search)-358.2(for)-351.7(new)]TJ 0 -1.2203 TD [(therapeutic)-218.5(targets)-209.1(and)-214.6(their)-210.3(validation,)-212.6(and)-208.2(in)-209.3(the)-212.4(design)-211.6(and)]TJ T* [(testing)-506.7(of)-502.8(new)-504.4(drugs)-497.7(against)-505.3(those)-501(pathologies)-509.8(related)-500.2(to)]TJ 0 -1.2266 TD [(altered)-285.2(redox)-280.4(homeostasis.)]TJ 1.1128 -1.2203 TD [(In)-334.3(this)-331.2(Forum)-335.6(on)-335(Redox)-334.5(Proteomics,)-335(applications)-335.7(of)-332(these)]TJ -1.1128 -1.2203 TD [(methods)-330.9(to)-332(animal)-329.5(models)-330.6(of)-325.7(Parkinson)-330.2(and)-328.4(Alzheimer)-331.9(dis-)]TJ 0 -1.2266 TD [(ease)-228.2(are)-227.7(given)-227(in)-228.2(the)-231.4(original)-223.7(articles)-229.5(by)-230.1(Allan)-226.3(ButterÞeld)]TJ /F5 1 Tf 24.7795 0 TD [(et)-222.5(al.)]TJ /F4 1 Tf -24.7795 -1.2203 TD [(The)-455.2(article)-455.9(regarding)-455.9(mutant)-451.7(LRRK2)-456.4(and)-448.5(mutant)-458(tau)-450.3(in)-455.8(a)]TJ /F5 1 Tf T* [(Caenorhabditis)-255.7(elegans)]TJ /F4 1 Tf 9.4211 0 TD [(model)-253.4(of)-249.8(Parkinson)-248(disease)-248.7(reveals)-252.2(that)]TJ -9.4211 -1.2203 TD [(alterations)-318.6(in)-304.1(autophagy)-314.4(are)-309.9(critical)-307(to)-313.1(pathology)-307.2(relevant)-311.6(to)]TJ 0 -1.2266 TD [(Parkinson)-342.8(disease.)-333.9(The)-335.1(article)-335.7(relevant)-336.9(to)-338.4(Alzheimer)-338.2(disease)]TJ 0 -1.2203 TD [(involves)-243.5(proteomics)-237.3(studies)-238.5(of)-237.2(brain)-232.9(from)-235.5(a)-233.5(mouse)-236.9(with)-236.6(three)]TJ T* [(mutations)-573.1(in)-563.3(amyloid)-564.4(precursor)-564.5(protein,)-565.1(from)-570.6(which)-561.3(the)]TJ 0 -1.2267 TD [(neurotoxic)-225(peptide,)-214.8(amyloid)]TJ /F8 1 Tf 12.5194 0 TD (b)Tj /F4 1 Tf .5564 0 TD [(-peptide)-218.6([1Ð42])-214(is)-213.5(obtained.)-222.2(The)]TJ -13.0758 -1.2203 TD [(results)-217.2(demonstrate)-211.3(that)-206.2(replacement)-214.2(of)-211.9(the)-206.1(single)-212.1(methionine)]TJ T* [(residue)-268.9(in)-259.8(amyloid)]TJ /F8 1 Tf 8.4917 0 TD (b)Tj /F4 1 Tf .5501 0 TD [(-peptide,)-265.8(previously)-259.9(shown)-265.4(to)-262.5(be)-257.2(critical)]TJ -9.0418 -1.2266 TD (to)Tj /F5 1 Tf 1.2519 0 TD [(in)-379.4(vivo)]TJ /F4 1 Tf 3.2942 0 TD [(oxidative)-388.7(stress)-384.4(in)-386.3(brain,)-381.2(by)-381.9(leucine,)-386.9(leads)-386.6(to)-382.6(key)]TJ -4.5462 -1.2203 TD [(brain)-485.8(proteins)-487.6(no)-486.7(longer)-488.9(having)-482.9(altered)-487.5(levels;)-486(by)-483.1(Marzia)]TJ T* (Perluigi)Tj /F5 1 Tf 3.8317 0 TD [(et)-399.5(al.)]TJ /F4 1 Tf 2.4533 0 TD [(for)-396(analysis)-395.9(of)-395.3(4-hydroxy-2-nonenal)-403.9(modiÞed)]TJ -6.285 -1.2266 TD [(proteins)-405.4(in)-398.9(neurodegenerative)-402.9(disorders)-401.9(showing)-399.8(that)-395.9(lipid)]TJ 0 -1.2203 TD [(peroxidation)-314(is)-302(a)-309.3(seminal)-305.9(event)-307.9(in)-304.1(brain)-308.7(in)-304.1(numerous)-311.9(neuro-)]TJ T* [(degenerative)-255.6(disorders)-250.2(that)-250.4(affects)-254.3(key)-249(proteins)-253.7(related)-247.3(to)-249.8(the)]TJ T* [(pathology)-326.1(and)-322(clinical)-319.1(presentation)-326.5(of)-319.4(each)-324.5(disorder;)-321.3(by)-318.7(Isa-)]TJ 0 -1.2266 TD [(bella)-333.4(Dalle-Donne)]TJ /F5 1 Tf 8.2893 0 TD [(et)-330(al.)]TJ /F4 1 Tf 2.3205 0 TD [(for)-332.7(analysis)-326.3(of)-325.7(albumin)-329.5(redox)-331(modi-)]TJ -10.6098 -1.2203 TD [(Þcations)-645.6(occurring)-641.4(in)-639.2(various)-642.2(human)-637.5(pathophysiological)]TJ T* [(conditions,)-374.1(evidencing)-375.2(that,)-367.2(to)-370(some)-374.6(extent,)-369.6(albumin)-367.4(oxida-)]TJ 0 -1.2267 TD [(tion)-288.4(is)-283.1(correlated)-288(to)-281.4(organ)-289(dysfunction.)-285.6(The)-284.5(review)-284.6(article)-285.1(by)]TJ /F3 1 Tf -27.9978 77.2217 TD (1488)Tj 37.6276 0 TD [(BUTTERFIELD)-343(AND)-330.9(DALLE-DONNE)]TJ ET endstream endobj 28 0 obj <>/XObject<>/ProcSet [/PDF /Text /ImageB /ImageC /ImageI]/Font<>>>/Thumb 31 0 R/MediaBox[0 0 612 792]/Rotate 0>> endobj 32 0 obj <>/ProcSet[/PDF/Text]/Font<>>> endobj 29 0 obj <>stream 0 0 0 1 k /GS1 gs 310.847 260.447 239.074 .45352 re f 310.847 193.663 239.074 .51024 re f 310.847 193.663 .51022 67.238 re f 549.468 193.663 .45349 67.238 re f BT /F4 1 Tf 8.9663 0 0 8.9663 59.7543 725.7825 Tm 0 Tc 0 Tw [(David)-463.4(Sheehan)]TJ /F5 1 Tf 7.3156 0 TD [(et)-462.7(al.)]TJ /F4 1 Tf 2.5861 0 TD [(describes)-468.6(proteomics)-464.9(and)-461.2(redox)-457.5(pro-)]TJ -9.9017 -1.2203 TD [(teomics)-352.6(studies)-358.6(dedicated)-346.7(to)-351(chronic)-353.8(kidney)-353.8(disease)-349.9(and)-353.7(re-)]TJ 0 -1.2266 TD [(lated)-442.7(conditions,)-437.4(both)-441(in)-436.9(humans)-442.8(and)-435.9(animal)-437(models,)-441(and)]TJ 0 -1.2203 TD [(suggests)-640.5(that)-642.5(redox)-634.5(proteomics)-642(may)-633.8(provide)-638(an)-641.5(under-)]TJ T* [(exploited)-231.6(tool)-224.5(kit)-223.4(for)-225.2(identiÞcation)-234.4(of)-224.5(novel)-225.3(biomarkers)-223.5(in)-228.2(this)]TJ 0 -1.2266 TD [(commonly-occurring)-299.1(pathology.)-297.4(The)-290.8(review)-290.9(article)-297.8(by)-287(Maria)]TJ 0 -1.2203 TD [(Feeney)-397.6(and)-391.6(Christian)-395.4(Scho)]TJ 11.6089 .0126 TD (¬)Tj .4363 -.0126 TD [(neich)-395.2(focuses)-392.1(on)-391.9(recent)-395.7(progress)]TJ -12.0451 -1.2203 TD [(made)-379.4(by)-381.9(means)-381.1(of)-382.6(proteomics)-382.7(studies)-383.9(in)-380(characterizing)-383.9(the)]TJ 0 -1.2266 TD [(effects)-526.6(of)-528(speciÞc)-519.8(protein)-524.3(tyrosine)-528.6(oxidative)-521.5(and)-524.4(nitrative)]TJ 0 -1.2203 TD [(modiÞcations)-348.9(on)-335(structure,)-349.9(function,)-340(aggregation,)-342.1(and)-341(path-)]TJ T* [(ogenesis,)-202.8(with)-198.7(an)-198.9(emphasis)-197.6(on)-195.8(implications)-203.2(for)-193.6(aging)-198.6(and)-195.6(age-)]TJ T* [(related)-297.9(diseases.)-290.9(In)-296.4(their)-292.5(review)-290.9(article,)-294.4(Victor)-294.1(Darley-Usmar)]TJ /F5 1 Tf 0 -1.2266 TD [(et)-298.3(al.)]TJ /F4 1 Tf 2.251 0 TD [(highlight)-295.6(the)-294.6(innovative)-302.5(concept)-291(of)-294.1(electrophile)-302.8(respon-)]TJ -2.251 -1.2203 TD [(sive)-321.6(proteomes)-316.6($ERPs$,)-323.6(that)-320(is,)-317.6(the)-313.6(post-translational)-325.2(modiÞ-)]TJ T* [(cation)-578(of)-578.6(a)-568.6(cell)-575.3(sub-proteome)-582.1(at)-575.4(nucleophilic)-574.9(amino-acid)]TJ 0 -1.2266 TD [(residues)-535.8(by)-533.6(electrophilic)-533.3(reactive)-535.2(lipid)-533.4(species)-531.4(originating)]TJ 0 -1.2203 TD [(from)-298.7(lipid)-299.5(peroxidation.)-304.2(They)-295.2(discuss)-302(new)-295.8(concepts)-304.9(through)]TJ T* [(which)-839.5(the)-832.1(oxylipidome)-833.9(modulates)-837.7(biological)-836.6(functions)]TJ 0 -1.2266 TD [(through)-320(the)-313.6(formation)-314.7(of)-313.1(ERPs)-313.4(in)-310.4(cells,)-314(thus)-316.3(integrating)-320.9(lipi-)]TJ 0 -1.2203 TD [(domics)-273(and)-271.5(proteomics)-268.9(with)-274.6(cellular)-270.6(functions,)-271.8(and)-271.5(describe,)]TJ T* [(in)-632.9(particular,)-632.5(ERPs)-635.9(that)-629.8(modulate)-634.1(antioxidant)-635.1(and)-631.9(anti-)]TJ T* [(inßa)15.9(mma)18(tory)-198(pro)14.1(te)12.3(ctiv)14.9(e)-208.6(pat)17.6(hwa)14.4(ys,)-198.3(inc)12.8(ludi)20.2(ng)-203.8(the)-199.8(act)13.4(iva)15.2(tio)12.2(n)-205.7(o)0(f)]TJ 0 -1.2266 TD [(Keap)15.4(1/N)16.5(rf2)-373.7(and)-372.6(the)-376.8(pro)14.1(mot)11.8(io)12.7(n)-382.8(o)0(f)-382.6(cel)16.3(l)-382.9(deat)16.1(h)-382.8(thr)14.4(ough)-372.3(in)12.1(ter)11.6(-)]TJ 0 -1.2203 TD [(act)13.4(ions)-346.1(wit)13.3(h)-363.8(mit)17.4(och)13.5(ondr)15.4(ia.)-347.4(The)-354(exh)13.5(aus)16.8(tiv)14.2(e)-360.3(rev)11.3(iew)-352.8(ar)12.4(tic)15.7(le)-357.5(by)]TJ T* [(Mar)13.6(kus)-234.7(Bach)20.1(schm)17.4(id)]TJ /F5 1 Tf 9.105 0 TD [(et)-235.1(al.)]TJ /F4 1 Tf 2.1371 0 TD [(spe)16.4(ciÞ)13.2(cal)16.6(ly)-241.9(add)13.5(re)12(sses)-231.5(the)-231.4(form)17.5(ati)15.5(on)]TJ -11.2421 -1.2266 TD [(of)-325.7(vari)20.8(ous)-321.6(red)15.4(ox)-327.4(and)-315.7(oxid)20.2(ativ)14.7(e)-328.7(str)16.5(ess)-318.7(pro)14.1(teom)18.3(es,)-320.3(that)-313.7(is,)-323.9(si)14.1(g-)]TJ 0 -1.2203 TD [(nal)12.5(ing)-264.3(pat)11.3(hwa)14.4(ys)-271.3(and)-265.1(pro)14.1(te)12.3(ins)-267.5(se)11.4(nsit)16.6(ive)-263.4(to)-275.1(di)12.4(ffe)11.8(ren)15(t)-278.7(r)0(e)12.1(ver)11.3(sib)16(le)]TJ T* [(and)-290.4(irr)14(ev)12(ersi)13.5(ble)-286.1(ox)14(ida)12.9(tiv)14.2(e)-297.1(pos)13.5(t-t)11.2(ra)12.4(nsla)17.5(tio)12.2(nal)-284.6(modi)18.4(Þcat)16.7(io)12.7(ns,)-292.1(in)]TJ 0 -1.2266 TD [(the)-313.6(ca)13.9(rdio)15.3(va)12.4(scul)19.8(ar)-316.4(sy)13.2(ste)11(m)-320(and)-303.1(dem)12.2(ons)11.5(tr)11.5(ate)12.8(s)-317.5(the)-307.3(rela)15.3(tio)12.2(nsh)17.2(ip)]TJ 0 -1.2203 TD [(of)-275.1(the)15.2(se)-273.1(to)-268.8(ani)12.5(mal)-266.2(pat)11.3(ho)12.8(log)14.6(y)-276.3(and)-265.1(bio)14.6(mar)14.9(ker)-264.3(ide)12.5(nti)11.6(Þca)17.2(tio)12.2(n.)]TJ 1.1128 -1.2203 TD [(This)-257.8(Forum)-253.4(on)-259.1(Redox)-258.7(Proteomics)-256.3(illuminates)-257.9(the)-263(power)-252.9(of)]TJ -1.1128 -1.2266 TD [(these)-675.2(methods)-672.3(to)-667.1(better)-676.1(understand)-673.6(human)-669.1(health)-674.1(and)]TJ 0 -1.2203 TD [(physiology.)-370(In)-359.6(the)-364.2(future,)-367.6(we)-361.9(believe)-359.7(redox)-362.6(proteomics)-370.1(will)]TJ T* [(continue)-450.4(to)-445.8(make)-444(signiÞcant)-445.5(contributions)-444.7(to)-445.8(new)-447.5(insights)]TJ T* [(into)-282(physiology)-284.8(and)-284.1(disease.)]TJ /F3 1 Tf 0 -2.447 TD (Acknowledgments)Tj /F4 1 Tf 1.1128 -1.8336 TD [(This)-283.1(work)-281.4(was)-280.7(supported)-284.1(by)-280.7(grants)-281.7(from)-279.7(NIH)-280.3(to)-281.4(D.A.B.)]TJ /F3 1 Tf -1.1128 -2.447 TD (References)Tj /F4 1 Tf 8.4682 0 0 8.4682 59.7543 276.8314 Tm [(1.)-501.9(ButterÞeld)-430.4(DA,)-419.3(Perluigi)-422.2(M,)-426.4(Reed)-418.4(T,)-424.7(Muharib)-424.5(T,)-418(Hughes)-426.5(C,)]TJ 1.2519 -1.2385 TD [(Robinson)-511.9(R,)-510(and)-506.5(Sultana)-514.7(R.)-503.3(Redox)-511.5(proteomics)-510.2(in)-512.7(selected)]TJ 0 -1.2318 TD [(neurodegenerative)-413.9(disorders.)-410(From)-405.3(its)-407(infancy)-406(to)-402.3(future)-410(ap-)]TJ 0 -1.2385 TD (plications.)Tj /F5 1 Tf 4.8135 0 TD [(Antioxid)-340.8(Redox)-330.5(Signal)]TJ /F4 1 Tf 9.6472 0 TD [(17:)-336.7(1610Ð1655,)-331.4(2012.)]TJ -15.7127 -1.2318 TD [(2.)-501.9(ButterÞeld)-363.4(DA,)-359(Poon)-357.3(HF,)-357.7(St.)-360.8(Clair)-355.6(D,)-359.1(Keller)-358.1(JN,)-360(Pierce)-360.6(WM,)]TJ 1.2519 -1.2385 TD [(Klein)-378(JB,)-377.2(and)-372.6(Markesbery)-381.9(WR.)-373.6(Redox)-377.6(proteomics)-376.3(identiÞca-)]TJ 0 -1.2318 TD [(tion)-473.2(of)-462.6(oxidatively)-473.9(modiÞed)-468.4(hippocampal)-473.6(proteins)-472.4(in)-465.9(mild)]TJ 0 -1.2385 TD [(cognitive)-744(impairment:)-743.8(insights)-745.5(into)-741(the)-740.2(development)-746.7(of)]TJ 0 -1.2318 TD [(AlzheimerÕs)-337.6(disease.)]TJ /F5 1 Tf 9.366 0 TD [(Neurobiol)-340.8(Dis)]TJ /F4 1 Tf 6.0655 0 TD [(22:)-330(223Ð232,)-333.8(2006.)]TJ 12.9678 62.8975 TD [(3.)-501.9(ButterÞeld)-296.5(DA,)-298.8(Reed)-297.9(T,)-297.5(Newman)-295(SF,)-298.1(and)-292.3(Sultan)-10.4(a)-290(R)0(.)-295.8(Roles)-299.2(of)]TJ 1.2519 -1.2318 TD (amyloid)Tj /F8 1 Tf 3.97 0 TD (b)Tj /F4 1 Tf .549 0 TD [(-peptide-associated)-345.7(oxidative)-342.9(stress)-342(and)-332.5(brain)-341.1(pro-)]TJ -4.519 -1.2385 TD [(tein)-305.2(modiÞcations)-305.7(in)-305.2(the)-305(pathogenesis)-310.9(of)-301.9(AlzheimerÕs)-310.9(disease)]TJ 0 -1.2318 TD [(and)-352.5(mild)-355.7(cognitive)-362.4(impairment.)]TJ /F5 1 Tf 14.5612 0 TD [(Free)-355(Radic)-358.8(Biol)-360.5(Med)]TJ /F4 1 Tf 8.817 0 TD [(43:)-350.1(658Ð)]TJ -23.3782 -1.2385 TD [(677,)-332.1(2007.)]TJ -1.2519 -1.2318 TD [(4.)-501.9(ButterÞeld)-410.3(DA)-408.2(and)-406.1(Sultana)-414.2(R.)-402.9(Redox)-411.1(proteomics)-416.5(identiÞca-)]TJ 1.2519 -1.2385 TD [(tion)-500(of)-496(oxidatively)-507.4(modiÞed)-501.8(brain)-501.7(proteins)-505.8(in)-499.4(AlzheimerÕs)]TJ 0 -1.2318 TD [(disease)-596.1(and)-600.2(mild)-596.8(cognitive)-603.4(impairment:)-603.2(insights)-598.2(into)-600.4(the)]TJ 0 -1.2385 TD [(progression)-406.7(of)-395.6(this)-404.1(dementing)-407.5(disorder.)]TJ /F5 1 Tf 18.2701 0 TD [(J)-401(Alzheimers)-409(Dis)]TJ /F4 1 Tf 7.4647 0 TD (12:)Tj -25.7347 -1.2318 TD [(61Ð72,)-329.6(2007.)]TJ -1.2519 -1.2385 TD [(5.)-501.9(Dalle-Donne)-239.3(I,)-233.8(Rossi)-237.4(R,)-235.5(Colombo)-239(G,)-235.2(Giustarini)-235.1(D,)-238.6(and)-232(Milzani)]TJ 1.2519 -1.2318 TD [(A.)-673.8(Protein)-687.5(S-glutathionylation:)-689.1(a)-678.3(regulatory)-689.8(device)-681.4(from)]TJ 0 -1.2385 TD [(bacteria)-330.9(to)-335.4(humans.)]TJ /F5 1 Tf 9.0915 0 TD [(Trends)-335.6(Biochem)-336.9(Sci)]TJ /F4 1 Tf 8.4153 0 TD [(34:)-336.7(85Ð96,)-336.3(2009.)]TJ -18.7588 -1.2318 TD .0263 Tc [(6)26.3(.)-475.6(D)6.3(a)-2.6(ll)6(e-Donne)-295.7(I,)-292.8(Scal)6(oni)-295.2(A)-.4(,)-292.8(a)4.1(nd)-293.6(ButterÞeld)-293.6(D)-.4(A)6.3(.)-292.7($Eds$.)]TJ /F5 1 Tf 25.641 0 TD .0296 Tc [(Re)6.2(do)4.7(x)]TJ -24.3891 -1.2385 TD .0248 Tc [(Proteomics:)-454.9(F)1.1(rom)-450.4(P)-.5(r)-5.3(o)-.1(tein)-454.2(ModiÞca)-6.8(t)5.4(i)-6.5(o)-.1(ns)-453.8(to)-448.7(Ce)-5.3(llul)-6.5(a)-.1(r)-447.1(D)-1.9(ysfun)-5.7(c)2.3(-)]TJ 0 -1.2318 TD .0231 Tc [(ti)-8.2(on)-375.6(a)-8.5(n)-.7(d)-380.7(D)-3.6(iseas)-7(e)]TJ /F4 1 Tf 7.1969 0 TD .4059 Tc [(.H)384.4(o)377.8(b)382.1(o)377.8(k)382.1(e)378.5(n)382.1(:J)379.8(o)384.5(h)382.1(nW)381.6(i)378.9(l)378.9(e)378.5(y)7.2(&)-2.4(S)383.6(o)377.8(n)382.1(s)380(,I)384.1(n)375.4(c)381(.)381.4(,)6.5(2)377(0)383.7(0)383.7(6)377(,)]TJ -7.1969 -1.2385 TD .0224 Tc [(p.)-336.8(94)-6.5(4.)]TJ -1.2519 -1.2318 TD 0 Tc [(7.)-501.9(Dalle-Donne)-473.6(I,)-474.8(Scaloni)-469.8(A,)-472.9(Giustarini)-476.1(D,)-472.9(Cavarra)-470.2(E,)-471.6(Tell)-468.2(G,)]TJ 1.2519 -1.2385 TD [(Lungarella)-251.6(G,)-248.6(Colombo)-252.4(R,)-248.9(Rossi)-250.8(R,)-248.9(and)-245.4(Milzani)-249.8(A.)-252(Proteins)-251.4(as)]TJ T* [(biomarkers)-561.5(of)-563(oxidative/nitrosative)-565.3(stress)-569.6(in)-559.6(diseases:)-559.4(the)]TJ 0 -1.2318 TD [(contribution)-365.2(of)-362.1(redox)-364.1(proteomics.)]TJ /F5 1 Tf 15.3311 0 TD [(Mass)-366.6(Spectrom)-360.3(Rev)]TJ /F4 1 Tf 8.5425 0 TD [(24:)-356.8(55Ð)]TJ -23.8736 -1.2385 TD [(99,)-330(2005.)]TJ -1.2519 -1.2318 TD [(8.)-501.9(Giustarini)-268.6(D,)-272.1(Dalle-Donne)-272.8(I,)-267.2(Tsikas)-270.4(D,)-272.1(and)-265.5(Rossi)-270.9(R.)-269(Oxidative)]TJ 1.2519 -1.2385 TD [(stress)-824(and)-827.9(human)-824.6(diseases:)-827.2(origin,)-826.8(link,)-822.3(measurement,)]TJ 0 -1.2318 TD [(mechanisms,)-396.8(and)-392.7(biomarkers.)]TJ /F5 1 Tf 13.731 0 TD [(Crit)-398.9(Rev)-397.2(Clin)-391(Lab)-394.1(Sci)]TJ /F4 1 Tf 9.607 0 TD [(46:)-390.2(241Ð)]TJ -23.338 -1.2385 TD [(281,)-332.1(2009.)]TJ -1.2519 -1.2318 TD [(9.)-501.9(Sultana)-347.3(R)-344.9(and)-345.8(ButterÞeld)-350(DA.)-345.6(IdentiÞcation)-349(of)-348.8(the)-345.2(oxidative)]TJ 1.2519 -1.2385 TD [(stress)-321.9(proteome)-326(in)-318.6(the)-325.1(brain.)]TJ /F5 1 Tf 12.9812 0 TD [(Free)-321.5(Radic)-325.3(Biol)-320.3(Med)]TJ /F4 1 Tf 8.6831 0 TD [(50:)-316.6(487Ð494,)]TJ -21.6643 -1.2318 TD (2011.)Tj 8.9663 0 0 8.9663 439.2566 400.1385 Tm [(Address)-339.4(correspondence)-340.1(to:)]TJ /F5 1 Tf 1.8779 -1.2203 TD [(Prof.)-336.6(D.)-333.1(Allan)-332.8(ButterÞeld)]TJ .0695 -1.2203 TD [(Department)-337.8(of)-336.3(ÌÇÐÄvlog¹Ù·½Èë¿Ú)]TJ -1.6629 -1.2266 TD [(Center)-333.7(of)-336.3(Membrane)-338.4(Sciences)]TJ -3.2057 -1.2203 TD [(and)-332(Sanders-Brown)-336.6(Center)-333.7(on)-332.5(Aging)]TJ 5.7222 -1.2203 TD [(University)-340(of)-336.3(Kentucky)]TJ .8662 -1.2267 TD [(121)-333.6(Chem-Phys)-337.8(Bldg)]TJ -.1454 -1.2203 TD [(Lexington,)-333.7(KY)-337.2(40506)]TJ -1.8716 -1.8336 TD (E-mail:)Tj /F4 1 Tf 3.2563 0 TD (dabcns@uky.edu)Tj -19.228 -1.8336 TD [(Date)-279.5(of)-275.1(Þrst)-277.4(submission)-279.8(to)-275.1(ARS)-282.3(Central,)-276.1(June)-277(6,)-280.6(2012;)-272.8(date)-281.1(of)]TJ 0 -1.2203 TD [(acceptance,)-283(June)-283.3(7,)-280.6(2012.)]TJ /F3 1 Tf 8.6118 -3.5724 TD [(Abbreviations)-337.5(Used)]TJ /F4 1 Tf 8.4682 0 0 8.4682 353.8204 234.1417 Tm (ERPs)Tj /F10 1 Tf 2.4503 0 TD (¼)Tj /F4 1 Tf .9373 0 TD [(electrophile)-339.2(responsive)-345.9(proteomes)]TJ -2.5641 -1.2318 TD (MS)Tj /F10 1 Tf 1.6268 0 TD (¼)Tj /F4 1 Tf .9373 0 TD [(mass)-337(spectrometry)]TJ -3.1131 -1.2385 TD (RNS)Tj /F10 1 Tf 2.1758 0 TD (¼)Tj /F4 1 Tf .9373 0 TD [(reactive)-339.5(nitrogen)-337.3(species)]TJ -3.0729 -1.2385 TD (ROS)Tj /F10 1 Tf 2.1356 0 TD (¼)Tj /F4 1 Tf .9373 0 TD [(reactive)-339.5(oxygen)-333.2(species)]TJ /F3 1 Tf 8.9663 0 0 8.9663 59.7543 749.7069 Tm [(REDOX)-339.6(PROTEOMICS)]TJ 52.4612 0 TD (1489)Tj ET endstream endobj 33 0 obj <>stream hÞbd`ad`ddòðtrt÷ÐvL)0q6q57‰Šÿæ+ÿôëÝÏi¬ù¯ Üìþ^!’âFR Œó˜:˜™"úù~Õ|Wþ¾Xtâ¤esWnæX¸rþ–)RÚ'5ôûüf–+¨©ëjjXØ¾´JnUÅôºi ¾'ë’—HOëŸ4¡¿n}övùÂµ…sš§püœÊ6yA÷Âù%Ýò|?§ýtþ~[tÖ¼îùó+ºkåÿ¼f«è./Ÿ×=KþÇ«ßa¢3!25ò^²Õ@dfÊóNÃ]8 endstream endobj 34 0 obj <> endobj 35 0 obj <>stream hÞTP1nÃ0Üõ Ž):HÎlx¨‹’uÒ]–hW@M ´<ø÷•'EÀ#w¤l»×Ž\ùÁÞôatd¿²AprÕ¬3qï šYIÜoKÄ¹£ÑC]ù™†Kä o•zVO ßÙ";šàp©®_‰è×~pFŠ iÀâ(d{Òá¬gYtäeÇÒW»µ·¸m5Mõ`š Ùÿ³»bÍ·fqÛTê¥mDÚÝÙ¬ÊÇ<˜•9…+—ÙÜ>ž|È^¹Ä¯ŸDið endstream endobj 36 0 obj <> endobj 37 0 obj [/Indexed/DeviceRGB 255 38 0 R] endobj 38 0 obj <>stream 8;X]O>EqN@%''O_@%e@?J;%+8(9e>X=MR6S?i^YgA3=].HDXF.R$lIL@"pJ+EP(%0 b]6ajmNZn*!='OQZeQ^Y*,=]?C.B+\Ulg9dhD*"iC[;*=3`oP1[!S^)?1)IZ4dup` E1r!/,*0[*9.aFIR2&b-C#soRZ7Dl%MLY\.?d>Mn 6%Q2oYfNRF$$+ON<+]RUJmC0InDZ4OTs0S!saG>GGKUlQ*Q?45:CI&4J'_2j$XKrcYp0n+Xl_nU*O( l[$6Nn+Z_Nq0]s7hs]`XX1nZ8&94a\~> endstream endobj 30 0 obj <> endobj 39 0 obj <>stream 8;Z\7=gGsg#kTh>O8GQ'lb"KRO[W,?1/jCD7?*->K:PIDn\kJ.r]o,GYEZN9q.S)M 94S@ML'%du*2[&d"-BY]8]UG,0@JT%b4!g9mfLGaOgRu?p>QiM+kqkmhbQNPDtu3` FmMn7f7(-!Rs=:*E:s%>\2C:$Jdck0`\Na*8Og@9cGu7I@ha>GW>N0!LQT0eXc_oW fJD-D*gc_lak'3CX/Y>F-I#/h"g5+rD+b&%oo8JS?bL`1pNJ1.LUtf['f2tXKn]J@ l5G@gBI>_o&[Il>gA3QBP.*A5B(@g%NhPjX1N%as]"p0uAKfsg <;$Z+\Z3'k*;skacAq=Oa787j%!nEu./>?5Z165Z=+q*j1GmG-351n$ldR#Jg;Alk hVm"f7frhN-^1Lhd>e[pe);5a*?Tn\aRfRFKGkMH 4okKJ*M*&DLFEuGtRAX36o$7 [;:$ao/!CN\20\JKDtrPhrr4K~> endstream endobj 26 0 obj <>stream 8;Z]"lOAJ#%"p]9s(245]M<1a.uDT4M&ek@:o&s[EW%l`5kO8rdQ=jCRAOck&aIS9 Y9Y-qs$bJn&76^Z!kpHb-P@IGbgk%EPo"cUiRRBiU,;s+crtkFX3/cg3F..Ok=ar> o%FA6=X.^r4B9q-D+o#(k2l\iWVNRXQ+i:AX*h='H&4qf-8^pVk7K@7^&Tg5rLu0- OhBcQK]QuoS_2`J4](jCo2>-*'*GmlgMH/:03@7^L;)HLDr&3VXfLH#H03se^[dBr Vh?Sug)kh-o$/qm$foi:^ERrsh8GA9dN endstream endobj 31 0 obj <>stream 8;Z\78%+()%-'&.I/gP:3ZhhMklERoZhT?C.?L8PD?)=B5\(UFhP&3q^Oe"[jhH); k6O4/BYXLm]D!%HSId4SU)0o']i?mL3IE37AEa.pRnON/$"s,f< A,l.?[DODN?SHrO99RO7R+mtI/WEiZ1Y(>^ag#0)ppHpqLs#RdeuM_B+R4)5\k^e= Q1;6Rat0^gGYRh9l=!7opu<0946dP^NrcKWM$!!JYn6$OaF9\h=uj.3WXu;ocg*7a \gPc80OGgSrK2O$o&)H'7e]Z,FPniFph&h^qS=+KSNf?Vll8):M<2heX2HLRN+,lT $d=[ endstream endobj 40 0 obj <> endobj 41 0 obj <> endobj 19 0 obj <> endobj 43 0 obj <> endobj 42 0 obj <>/XObject<>/ProcSet [/PDF /Text /ImageB /ImageC /ImageI]/Font<>>>/Thumb 39 0 R/MediaBox[0 0 612 792]/Rotate 0>> endobj 57 0 obj <>/ProcSet[/PDF/Text]/Font<>>> endobj 52 0 obj <> endobj 53 0 obj <> endobj 22 0 obj <> endobj 23 0 obj <> endobj 60 0 obj <> endobj 61 0 obj <> endobj 21 0 obj <> endobj 44 0 obj <>stream H‰tT]oÛ:}Ï¯ð#3,ŠõaÉzìuèÅÝz‘zOÛGM¼9v!;]{ì~ËH1éÖ¡C€„ÉCžCFËw72Û³7Õly)3™U·3Yoråø9ÛF—Âj9c„µRgÕa–sDö ª¡¯ï3¸œW_gR Y”ìfÓ˜R“—Ïàzýñ}Š©bé„+÷<ãí_à=Á›ç±««êz}uñoJqÂkuÊ9ÙJK¡v™uh.e}‚uØó…ÖF”ð_¦0Úfœ©þAkä…·Ê&¸“©ò\xémf•…tžÑV‚ ”PpÑuu£…†7Çi ñÇ|á…„ÐmºÆIîÑ kd¦J-Œ5E†Ò£*‰•$:/”÷¹(½T”¯û-•Ì……«±ÞìÏVu×…u `5ô}x¹“£¤Nûß{PÔÃòR³%v`yx'³ðÂ¦Ðœt±§X7çš¿éø”[háœUÌ#Ía¾J8hûq¾P;…:2KœÔ¡þ:D:`>LuÜ¢f`JÁZ0Ü²Û@¨‚ƒfjïŸò‡‡G¼Cç.ôç»¤žr9*Ô·SØåh€ãf–èhÚ0žƒ>ÃúúfÉ’®?Ü|ž³Ãþ’Ð!rÈpL™î†qZ 8D÷ß@WOíÐ×Ýë4“<[Hûå²j…ZÄpOZql7ö¡KIp«ÃmŒÌ%ÜSWãHô;8ÛöGƒ5°µ7PariØ×÷ –ˆ/ƒ7û‡G”-àæ¶ÿ‡íëäƒïû¶Ù“©Ñu¨ÏE:™ÂiáMóv@{ˆë¡ ¹ßHX.[½Oýz{ŠÇf:Æ´ð¦V¯Îûÿ}X2{bs{ì‰±¥ùç¨3š>W>§Ë‡v‹"”€t¸Kw´jgez‘BŸŒð1¤f4¤·Úm²TÚ.aPY‰Æ¶ßuìÑ´Ñ9Ä^s¢M¬™PŸDEBåoßž#Ì“x¤W)û)Àvh« endstream endobj 45 0 obj <>stream H‰dTË’›@¼ïWìQNÊ0`àœ\²Ç”o©Æ ›©ÆÃ>~v¿%j ^oUNÍt«ÕÒñéáøíáY7ò.iÒ†º]bš*-ÉîövI±¯Òœ\ÇSpçw7í’,—´ÒêÔ:$ÒŠžW‹$ÉØË}É½àK‘hæÎ¿%8ÐÉ.ÜÅw+j{;]xÁß&-èÕ…E–Qèá<Íè:ûÀ^‘ .èäC“!½qÇÁŸR,Nðk‰NvØ¸”Â„ÿŸöI–fMùxü)¬SÇJ¼¢y—ä#ÿæ:Ü‹|È«<i 3/>ãÙÖO¨(§Îç§·¡¯´³ñ¬øyæA¸éÈâ;Â¥„O°÷55'´ÚV¸é¹–è4.„-¤„A¼Ü³ó³§’ƒüLÒ›îF³_³Ò;·¡¸éà"<*áÊ"s|¦!·ÄS%ËWêxx·3²mËWÁÍ$/p÷ý®M¾ßWQ;@j4È¯9åE „am]·u[XBâ¼¨%«µ«‚PG ’(’ÏgnÅSy‰êgAõ æƒxx´@8”pÆ0°˜C¹U*«…_S;Ç¾J‰h# 'çaZ˜u®µCEl°ñ\Soµ™”Å_6ú±rÌëÇ(à•µ ôÐaMG}<µð¬QIÏ^è˜ –5Ò|˜éÅ/7K2=HªDdF4»òÖùdƒ–(>ViKž6¥°ÍÓFÌ#½–ý,ÌVÊòóBƒŽÆ›ìù[Ñ´ŽQµÏ·Ì/TlèýµW"2º‹óƒ¿8ô<#hù)Âÿ¦Ç¶ØÖ€iJ/0i!Œ.)b ò›¶n{D1OÁ¿Zíe×N&1¯˜“ T8þë|JýSçâºBÿMþk1 ¶@lC£‘‚ÛuV±Ï¤X;î6°ãrƒ¼?ñÉBæ)NÊ” ñÉ]‹ßÆByÖØšØ`·»qi…>ÚmŒAËD º–—+·î£¸%´,,Q ¯„¾ì"Ù»bêÑjoÈDÔ…È¸jÇU¦)`È¡M#z^Ý&?wi$›Ñ±×›ª{|É›|xãê_ãˆÞÔõùøO€j{©Í endstream endobj 46 0 obj <>stream H‰tTËnÛ@¼÷+r¤[Ð[ö±@Q´ŠoMkimocŒÕÚ‰û±ù–rH9 Pô$jÃáp–ë¯ïÖïßý¢ãíl‘¥É’|tæ0[äM™44lUIFÁvÃÓuùøüÀò¤ Þµc‚‚¾xDy²¢¸·kfŒz ¢}DØ$5]¬ ã\1sj‡~3[4ÌÀyÛa5ãã’I1dš_ñ{£§ÇQVh<Ú6†¡Çé‚ñb¸(HCw4[,¾ý¼›Íµ¢†Œï4\’Ù>{/³ûõ¤GòKFéÝ(@Kæ»Ø˜ÌÊªâ¿ÞrMKÚÝp`)VLiçìˆíš!÷æl\˜Ç6¹Í) Bs•ØNYZ#wht;ïž‘ª¤Öø¨H5=š‹1hMºœtlE&º"¥Ü†|E6\“œ|§n(Œ‘kwÊÙïp}ä^¿ÔÿVv!Z–Ì høë:ÝT4:å]1ïè?ê_hÛS’¶`œÝ•Ì+äÙÐš†®•Àß¸pK:;×Â¸&-Ö®´®·šõ¼- èhç¶[¬¨Xgœý¸¿ŒŽ;µ“ªØdŠËù2qJOoY’ª›õGh`¢2Ûãä"½Säb×©«›J–"Ý_Ñgë[aEóëRÜ;p.JNÿiÏéÔci ýýuó¿5µÜ“.Õt+/®GËÑþV€Ðr…¬Xµèz…´‡‹Ð¨è{p»I^¯Ôá"1~YÂ:Áž$þX‡]{—r0ØW]ò4m&a‚Õr9•?yÅ`( Èknº*ý,ò’qÇÓZÕô›Ÿè´ZQ0~'ž( (·å·‹BhÉ°QØ†Íl<‰‹ÉÊRÃm¥°Ó“¸TôÊèÌšèØu¶À»bÓ*w`m‚qBZIF‡žE¿û×—ñá oàÏÞ² á·¬a^-Oü–ÌY%Î@Éxt€ÇôOW¬Î{€Ô,d%ÄËÃê? Þ ÞšðÀìT’Š`›´Ï:Á®Ó98\‘1ä§é^æ9yi|wñƒë2£Í™jQ‹ÙýÍ_–i¤é endstream endobj 24 0 obj <> endobj 54 0 obj <> endobj 56 0 obj <> endobj 64 0 obj <> endobj 47 0 obj <>stream H‰TTËrœ:Ýû+XŠ[#„x,Suë.î"©²g—d!ƒr@š0ñä+óù–ô‘˜J¼¡ZBÝ}N÷é>ý·Éúçî3ëÝ%Íš¼eÚ_ÓL³Ù³¾Þ±³òÂá0ã‚²õÇ^œ‡²Ïç5›vºkÉP6°÷•l0«V«N3°÷ç=®ÛÒ‚9˜½í'ï¬¡½òƒqP‚ý>ljvž®kŒÉ „Ñv±3Á<«m:þqÁòíá?™ðäôr'Š¼%rI‘œþ%´,! ìÍ9bHŠý¨÷xÐÈ“-ˆqª§Ëe[v·0Á¯ Ü¼¹¿‘áUÛü¤OšA€Ý GýK™—¹I´$é£mª¤$¹vEÑ$§åŽ}HO¯äÒDRc]‹às˜ 9UB$¢ „eÇáô™-‘5$ólÜâHOû¬QnY£pÇ¬ïqâÍy{£¤¼Æ{}Q¯ª”’z±)?êmÅ?Aµ!‰!JvóÎx^–…ˆ1¼V}T|U¢ÂîíJÃOMlYUŠ8…Þ¿p&¹öºÃ±c_Øã§§‡ÇO_R\u‡sH\æ¼¦ú½Ëk÷E{·C·:>»uË6¯ì:å©]"È˜ÍžyÆ$ÄÇaG 3þý¿š ;üô_}”qšQb6)ðä´&${Ö Âi“šZ=iÞüÐÃ=Þ¢ß'ÓOx‚µ¶¨k|-Ù¬Õ;TÚÅx43ñJ"˜u€PDÊu)caI²n'0˜ëæ÷~ÛC'–Uí!´R`(_vÛÇ¥'VÖ«#F‰Ùs4€Ž_=Š‡äœü`Ìz–€ endstream endobj 25 0 obj <> endobj 68 0 obj <> endobj 48 0 obj <>stream H‰lTMs›0½ûWøˆ;A}€¸wzÈ¥3ß’0ÈFƒ\“ÐÛßÒ·’MÈLn»Zißî¾·Ú?n²mš3Î3±ÝÛ<%?Þl[OöÅìR.+¦“‹w“±¹Ë“Þµö_ƒné,g2éë9š:ñf¼ž'òJ¦c§Îø{ìè]O¶FšÖzÓL»_ûÇÍþ`]„u„S”¬LÜ‘,guoGN‘ÔmÉ’¬ $Û^ QfL$Žp Ž§SçÝõÔ‘[¡:”M‘ï‰2€B%ÜfPqÞÔM mØa2¾7'Â’'Ï‰e†=CX½ò6µ?¸a>S©ÖEÙÃùëÎá@¾gçš£ó .Ãêì8Ù6p]®tõ@ŠdÑbžº}©‡}ÂZ Y*¦ÍÎ$D_Ñ*µ×f¢Ô»¥‚feX«2á*Uq˜ÉRˆ„ž¤"aG•…Ô’*»©7Ðç Þ‡2EÎ¯§Ú“X³pÓ“E«a¬‡|½sx³TnB?Q)"+puá^F”¾CÇ-ØÏ@š*1þÛ¯AŠ°igS·±¼Âs÷{¡;ºÁ×Ë)+d+¦±Ì>Gi§óœ~¶¸Í}¹Áämò¼Ôì½7^å,Ï¹þHÝOÓº76“‘É¸Þ6#ä½¥+jž¶ŠÎ8¾…Œ`0(‡Î²ÄôÆŸb—ñ{ð(»£’ŽÒý~Èspm{j˜…O,üD&{œ£sÚš:t™Ó—øçZ¯£:¨m¥‡z$Ánÿ0`9¥$ endstream endobj 49 0 obj <>stream H‰lT=sÛ0Ýó+<Ò½D•H‰’ÇÜuêÔÁ[–h‹WŠTI*‰ÿeRÒ_¹óðððÀíÏ§rõRœK¹ÚþxúÍúìQ…õK-eQ³GmÉ«‹ ‹£B³Ù°Ù»¨ÜDžlÙÞÅ‘¬’å§¼àÌ«Á}’#ŠŽ}´`´=æÁÀë·íµx)rñÅÊ¯_DÛsŸz€¨ß±ˆ›¢e!z]WèõÎ:jgÏ'œíXõo³[ù}Å~Hï x•MŽ…ôßE%ÛoX&GàšVbæ½vÆu†NZda‚Þ»ÉÕ/†¸iÚ.µŠïÙìB@X:Ç·L5)CJÎ»¢,k¾âX´jÛÜåŽõ§@ÈÔ3òÁKÄ3)¤ÙÙóQEè‰"4ËB²€9»íÖUaCq„˜í*Swt"pR^½<"ø]ù ÷yh°Èæ2¥A´è@&´á8£_ 6ƒùQÃÜ,ŠAû|\1ëü”øÂÉ‹M™žoŒºG‘pÔQÅÂ2ÏŽrrÙáóádaÒ=¹]¯Ž‹Š§‰ôPQŽ²jHKš$o«M¼éŽKÕâVõ•p‘…ÛÒp€)Ù µ '"œœ†ÞœÈ¦ŽÁGv…=Ø|,ÙþY3=Q`cN+ÙYàïi¿,éuIŠB¦v'Ú{u›‰ÍÕò“Ç1€.8uû^»%ä‹¬{4rèõ@ë,$¢> endobj 50 0 obj <>stream H‰lTËnÛ0¼ë+t¤‹Ø5I‘’®}\R´ES=$9Ð³DG¢cçgó-Ý!m§Ì].ÉÙ™Y®³9_p.ªœþ…Ð:_}ÉnÙ´³{ifsÉË…b7?ÓRðEÍÌÐ~ô#"±ìæ6xµ¨˜mÊjÖû)¤´d~ì€ ¹àl²Ãd[DŠŸSIÉv£Ö Óì~u-¥L@.lgs^£n´?ÎGkšàžè1±¬Ùçç íäÚ½®ã°õ“=[ç»´S0t ÎHÔàL° Àê=kvD:küF–•fþÉ¢ûª¦°EË:‹˜\@O5§¶‰&l)ZnöC“Þ’UIHü+ðt:_€3‹W±5©——Æ)¼™Ö:"Ø§¢Ëmº YÂóÎ5¦KUšñÁ†Sah0ETkIr3ÿ_†³€Ÿx• dÜTTéIt¬ÝÚtXÔðHëw!U×¬ßwÁí:`Sí¿r/•&~NÜST¢¹Hœ:ƒûJªØ™qþž9‚kö!9””Ôfó<C‹xýyCØ½!¬JàÉ5’¢¦çZ·ÙØÑÁ™®Ã¾„#0ª’Ó ¯ªÐ¥;?ÀW‚4T,x¬8™ª%SŽiƒœ5î’œïMØ jqÒ¾dë=Éã7<À¬5{±]W„ZñZD{Gàf‘ìâ{×L©°`wŒ_¥RÍôÝKÍ¶&îKhÒuþ@-Ï›‘?“Il:¿†w+9lG=ÑÇà4qRÆ†? €èÞiÎCºCGØBÂl'c§o'O`†ÒôY{õÏƒ{ PF‹®P…Œ4OÖLvnH¸&ØSž³ÆvEœDz±QÒøŽ£í’Ç”¬‰½µ k“¨_WÙcÆs—gŠ´PEN3‘úLÁË‚ŸÝ%A>1NÎáŸ| ƒâÇóotå5ýÿÍ‰á2?ä|™Ïoï—y›=R>U½}±écºÏŠšÆ¹,iÝe¿³_ôû´ÊhÄÊ²ˆôQát©¦Ïš®T^Ò¡‹|Õgù?~±‰è endstream endobj 51 0 obj <>stream H‰|’MoÓ@†ïþ>¡1J¶;ûáµ¹…¦T†|HÔ J7lŠ!Þ Ç-ô/ñ+™±Ý <“Ýyçg0)¿FNäNªXÒo ‡©èL—M´¹ÿ^µ]ãC’ ]25& ‰„%V‰.¿ø¦>&¨„®}šð%'.}è|Ë ¾o¬È`é›»¶ žs%Ülk¶þØJR¯Âg5ŸQìÛãôu› ~>2gâ™Há0üKâ³û:Ü³’vdøC¨©¼îžæÌÆ;RxØ~üò»ð?©¶#-D:Ÿ$ŸÊ·Ñ”¼K™ÇôE¥ó¸œG§JÁ -Ñs¦i…Fåâ4.ÍlœJ‘i´Ôÿ™['”ÍÿÅ\kF;2§õÎs$‰þ=Rºw>³V²Ô¶ÙÏeËz³å…É±Êˆ2¥¡èª=Ã³å¼Áãr·Éš>stream hÞ-†¥šF1¡ 7Ï˜•+NÉN1™sLf}ž1u¤(†-[&Î´Ÿ+Î4æÍ+éêdã²•Æ¼Œ½˜‘+êÅ<³>Õ˜¥7gŠ¦%blF¶)¯ Ç(†E‹úìÔQ&³˜A÷æ®0äf¤fèÍÆÜ‘ïc`dt0*†À0Ã’3,£e?èÀŒg˜pÂLe˜X“ gfË˜” FÁ(Wf³€ÙÈ<‘M-•ýUö?ù(ù4yš|¥¼HÞ&ÿÑAãã°Íá•B©Vd*n²Ù8öö&ÛKæ‘\RCÈ¥ œ§Ü¨¼¢üÍQpœÓkTÙbU¶Að<çðºÂ¢º.á`¢m ˆÖ¹¨$³ŠÒ¢P£É'*p…o8˜¶œ¬(BUƒÉ5DŠÇ@‚;l‘,öƒôüï)UÒëtÎVDŠÐ™…·$.'áÊB<â^äkza8,é¸í¨‚’Ž‹[ÖÒtºáp{ó‘Œ¤9™K(Æ4îgcsôAþ|ýžÓÕÏ'>FotÖ†c¿)õÏ™xd’KýÒÔÚvüb ÞB^ŸssM±á1©ÍwÚ¾¿»wz2¯‚%÷êJÍá[‡’uAIésgÍ®ûð2‡lÕãIÐO.àÚß¾Ø5X‚‚—ÃñÃ{^àÞz¶ªõ€P^Ì¢OÉŒ¹34‹—íjÛ ”)UE° †sPCZp8A+¬ÃVöX 0UúWNºñ‹1DUÔé ç xÛÓx\8zd÷™óê›y7øújËþ×êÛAŽ‘<¾"àeÆA9s&76\Ÿ.`,‘–* ”t4ÄÏœŸ/`$=Ï*åso7Œá˜©Ái8]p–Á`t˜ü ]/ –Ì˜¬ÁsÀ8Xô¶õ8×éW }>]&°î"˜a$¸'ƒÿ"à ê%:sT¤Ë/Wc:~`ÀP%à0¢J”^Z œmO¯Aj‚6˜¯a ¾†R¢a%œåà:]¹ã —"¶ö@KhŠÁRºµïL üÝ’¶€+Zib)¬ö¥,‚.¶v¶˜ «ÔÎ¢‰âEéY97Û3¼ ¨¥gl¹íˆ”i;dszT*b1 ZI¡-¶J´VRÌ…“€öÀæ”§Oas#ô@n>îë‹› ØÃƒÖ9õàd\@IÖéœ‚¼*‘FSÅQÚ!é0_!AÝ(ø /i ÒàCå¿ŽeGe–N@Å;2½á Œ"àPaô «X²-CÝ7$³ªtï5¨3kã÷ò7w7vÜS_J‡!˜Àãovª¯sqÊ®¯Œ‘Æœ‰‚*ñ,çšQÕíSË€óoôÙÍcÄ 6ëËUçÔW:v·ªO2·ðT¦®’xðÂ ®YŒC&`(–ƒcŽp§€í,8S˜ þ$du$ºåw6–ð*Qê/uqEµy€!ËÖe¤È*ØÙ÷³e‘1úd¯¨'_ðÒjç(Ë#ªg[äuùù§W50È}˜A]”‚$'Lð¼/åÝ°f]!‹ÑLøo,´9°A`(ƒ;³@@Ú(¹sà†ƒëBQ†l}Êƒ†|·¥êÄ ÍásEñY9ëW 8`ðÙ”Yžj”ÿsÑý§Í'ð›³Ê7l5;Âˆ]duÅšíjü˜››2-ÇXÝf9ñÕéJÞRYW¹c»# pTs±fÿ€ôÛ÷~ÜýÓ¯Ýõ!A<®‘æs(Rñ_+'q/å[4p±ž=èä¯Ÿ›±B(¦~ö‡Yœ97:rH1(-Wëººø+[j+ÒÁƒ€î3äipr(-ŠPT´ /Ì‡Ù'À÷ì½¼ÕÎ£ˆ[‹ÉÁú6 :yúc,»ŠX.í¼pP(Ÿƒ‰Í‰zù¨þ^÷¯»ÇŽIð7?oçU’ FsÆµ)ù©d7ô4n$Ù›pè)\³õ1he$hŸ¼=.Gxânl=ÔtUÓ|vùØ‚½•çK‘Ü“£w‘“eÕü1`IÙŸW•4#âô(ì}Ç ¢’z$íçBŠ•‡V§X†ÿáêô—àòèÐÑãuö®£—–ª[»oßç<úd+Àq>È5Pý%ø=¤2¥ÅZœ-GOßmŠž«ó 6ÝïàiÍ_§§ÛöÓªÜ¯„$eÅÕ^¶`„Îr6‰U,„L‚{´u†ŒÄ…¬4¨O&êíÆ>:í&Ý±ô½&)8±èÒ]ô—¿¼¶Ä?Ÿ–þíÇ¿Ô™éµþñ]°ÕÛ/ƒ;Ä²«åê£ÒØ…<þÚ·”í{Zn?´<„ÇÎwaŸøã˜a)q™«ø÷[-äAkÓ¥îò)©ï¡ÿ°?x‰Èu¡'\ &b"pcÀ“î1$ÒÇ5:ßdòéèØùm»ÌN¿h^…Ý—i¼PO~ØÙ²¯ªK‹«xðP–__¶^3.svR¶Pü3ªiÂ•J„íZtÞë©AÝ\ï‰Îƒ‡×Ôù«Ó#M Íô‚[ÀÍ@_ª‡ Ý£˜ƒ?M¤®Û¶¿³³*-£‚·+o¶Û³Ï+Âûv’Iµ¡_CjkËÊj…7Ê’uëJÖkf–T}'@ÓãcèÝH%B*«ÍÝÞtå’;‹£ $ØöÛ»ê‚u›àE‚mè÷ Ò‡Ð>#ØnøÐÚ±^ä¡4ˆþ<´ ²*©ÍÅjäþ/À1+© endstream endobj 63 0 obj <>stream hÞ´Y TS×ºåä¤Æ¡žšäÔs¬¶j³uBœÀ@q`ž!„„ ó†@Îáœ¦0J˜aç±NµÕÖ¶v®·Uëí°ÃÝ¼·Þïë²ã«÷Þ·ÎZÉZ‡½÷ÿß?ìïÖV6£¬¬ÇoÞb¿Î~ýkëbœ–9,Ú0ün²…ó\[ÿ¡T`WÇ=œ÷âKŠ‰ÃzæçuVÖè±ÂG[gõÒx«Å˜••Õj++{‰•b”U†•ceµ™°²±Â®Z}k=Åz»µÂZm]bm¶¾?ÊnTÁ¨ÁÑûGŸ·!m”67±—1'L#˜"¨Ægãj|Pxôù3_<ûÖs+ž+³cÌé±¼è5Q”èÇq•ãŸŸ1áÙ ‘ÇOTL¼òü®ç{' 'eOú†ðx{!ç…G“·N>+#þT¢’4IWKÈy¤žüàE×MÙ:¥ZMUÐSgL]4ÕcªlÈ(‚&È±±L&äl(/çB½Ä‡´ÚÒ,aIV‘€44.PD~ÃÇ.÷„—{?xë®ôBP³sPœ:5…Ú´KHÊõ“ú{ô¡–{9lœ)…Öw–ƒI7o4ö¡dóí!K+ØüBúÓKš:,-&!=‚tÙÝØâBîë<EZšSžUNõ2L_†°6·ºÀD ™|‰Ó3ß]úîRá™gŒ¹`Í/®6wï¤¿DûÁ€0w×íhuSÒ©fio^ïyJó¾·„§®÷¾×t'¥D,O“§†fdR®öÞT–&SÐ•€B0),vR`{LB0žŠ3ap&».‚›¥Ðé&´¯Âç)ÑqJ€WÁó7-p’‚ÍkÁ"8Œ¥â"0 „ãÁéÐV íàr(„“}ðãˆPu˜Z–‘¹$`•·C©ZÜ]yî³·›¿ˆ@×²ô,¨6ë³°á-ã³‰æúúÆÆð†0…*\¡0©šhÑKù`(±S0$ü¯»Ø( ¤ÇÀß4`>Ø¾<_†þ è—Âô·æJC .!€Mœ wÁWRà\ø4ØÀ0^C‹¢®YNE@œÃúœØéP<ÅÄªÓ©u<ÃîÒŠ•8w»‡ë!{zXöÚŒïÕÅpñ|ŠA¢.dŒ5RËx²ÞQ¶Bf.E•×pîÖ-î]òÝ[,û>5ç˜uMÂlˆC¡â$Ø \±O¾ì>÷‘ô¾ÓçpÆÖ±û½)W¶g¦—Ð,(éÃ®Uv•_#?Øi»]µN‚/"/[²ˆ&ÁÁ3X‹ábÛqòêi·Í›÷¯_ž”ÌsItêž| VTm*n%¿ìq^¼ØÕnÞÌ}ý÷”´*Òµx_®¯$åÐ™ÔLCŒûz×ÑWKé½gÞ~ípÚ8îŽs÷¡¡-`±ß¯ñe¨íZ!?~‚;Iž<Á²'rwæ«‹×_—¾ƒêÌÉn¢ßÂƒµÁl0'4æð@¤o¢RõëT°}Èß…ãeÊ@aüpÀž·<"´0?’z½Ö”S¯3IPäµÎ.ŒéäÂëœé¬,=´É†Y¾£ëìh¬9CÞ?·aêtçõÞfh‰£=?ŒL>è]áUê-Iª=•Ñ@‚—ÁL„k>»ô&îw‹ŒðC”,”>°q¼ mìeA~®t%ØòÕ#`? ,Àƒ*0èµ¾íà)”ž…“Á\ªÐbCÜëX±b¥lþÜi`ôÇ5l]a5}øà™†>Ru¦ˆ(LÅ¸²r®Œ,+gÙ2ºë‡Ó¿l€#øPÜˆkí×1kÉuëx=–…q!¼L& aBXÕ(È?ƒÏÏ3ô“À(Zâ´Sˆü,Ü@ÀÑs6Ãgíû|Þô¡×(¶o^"…øç[€5lîƒçlè²m§Îv^=öŽô»%GPuCÑÑw½tËÛ…»Î~õNÓÉ·»¨Ê¯¯êý‡ÎHoõwß¼udŸÃöŸ}a(´ß 2ò¯ýÖO)Xb÷”@ñ¼—!2|u!x®®«¨ÜHÝ8§öp<¡ú•dâ`3x›˜ëûÙ‡5}ü=O?äÍpÔ é*÷õ+GÊzÜïÔ(øÖ¦¹¾á‰wá¨nGZÀ„?l›@<ñÛM lpXC,uY´k* átÄÄV°óyô½XA8Ò³§9‡æ¶UçÑïfl± aÆú2ûIˆÏ@ÈzÅ™mïŸ5·i§}ùZßò{@ “^pWÁ Ôà–@èÖ ¾@&¼ð‹ôÐ¼,Â#y óÆ°è³C¥ÞŠÍÐa=|+Ìt"ä•ƒl]Ø¸qèU±:".&’ éÜ!ÒÜÉ²ý¨^‚tX˜.!·JZnºVXE5\Ã@· âXQ¤!"Yš›ÃR#uvª—k#ô²l/Ú'ÓÅóêu¥$µJ]ŸnÍSü8˜c¢;û¡Ê‹Ï¤"Ò°hœkoç:Èöv–í A¸æ˜r_ ž™ÕóŠŽâñKîžÿRúã’ÖyÅÚíbœI¹Ïí¦x»¶–)Öæ¥IòÕ|D ôoÐŸàVq¨ž&Ýð†£¦npDÝRÉå‡Ó–{6ù f®žüøZôk³V¿®ˆâ¸xDÆöÁEéE˜Ìsi„ ÝP Mn`õ08uÖ¨›é¾„®„p©C~¢ðdÑQªÂ}aí<Ú¼"Û¾–^½ÍkÄ¥0,…/‚Ì‹*[ÏQˆâ|Q éTXâ0¾£½Ü‘rºèÏ™Ë†‹uB0vàx ,—‚=p.ºx|³(ÖÛ‘ÙBnqä¹Í\×¯À½Cä7œàZI”ÔÓ¼ I·—á¨}tÄngí~R¶w%âu,C2™jJ“–ªd‚GbÚÞÂu’—n³ì{4{ë¶®—<•w©¨Ÿ dîLñNÊ¦Å¿¢]A>¦ ´àº¦Žœ~òbkv†Ökùt.Eï$n°íLg‡´ƒïäº)… k/›Â¤geK2Õ²ì¤{0ÇËi`Äó|ù6{’.ÐrêéÖ6ü¸þ¬¡—â¼8/—ùÚ×I—F°_[ËgÿRdaàâ?`¿÷Ïìoþ#ûC®øÏäeG²îÃäñ'Žæ#ûŽæ0'F.H.5WS$É40¦N©¤Y¾¾O`³²ÕT¼Æ%a5 ý™ÜÁÆ`p¹r8åÐÑ„öDé”C'‹R%ž«àxjà8 ª`.Øqù&°ª«û„v¸9'×K™‹²ë0ÖÏõ#ýý8Î9üQ&fb Ò¢åƒî–«D'oÊ7PyEÅ¹µ\¿õof¯ëIºypüÞß„q6UÅz“0Eàâ¸TlÄŸîˆ§æDâ\q=×K‚Ao=ËÓ0òii†. ì©ÁþÑyz#âÚà¬**#)-–<“[E«5ú5›«góÉs‡Ûèkf}t¿å÷ûDQ>ø~ŠqMµ\-YSË²•È—>ž+?P#+ dÖÕÔ—š8I5âld8N*ÃyNN«ðÌä„¤$ 6ÁZ„þ‡5•z%þdû3Õ¡Æué*Ë~ñÏþS0-ï´P.HÝŸ£‘¥¥K èç$²,¼þ¤Q]-ß3l”UÊ9)æ– „–“6òRÎsaÈ“Þ_öÍ'ñ¢~è=Ò»º¸v²«ýñ]å‹äSu?ãµ¸ñ8hú3 vWôVvƒ‘¸¤¾´¡¬^È¹ žtÀò)ÆÆÇ3ñ#«¼»J–±HX…;°ÈÁ8Œ¡0 M"‹Q'‹s ¼iý =v|Ž4—Üf_€+¡Û ° 8€å·ØÓ¢Hï¼€®(³þùà ¯éK·9ÚFGëò£é¢`,ÛhdŒ$«/POÄà¨žÙÍº:£»|¸oAŽÑÖ1†¬|äXš.<ä_©ÝéOxðþ hµn§ë†TZ‘ÆªxMª¸"¦2®<lƒ9â’ø²„’x!WSÍÕ55,kBFòÑ¹IFt•[yÿ °–¾í{¾®¥XgçauïÌs{£Ýœ_ÍQe—¥†8š{¸è8Uî·Ó´’„cà‹ëáüé—ÜÀÂxúQê-Õé¬E»ÚÙuödQ×0¹€óÈqÍØ+Ll¹sƒDãëÜ;(^‚Emð¥2N(õï¹.}ðþÑ‡z2¨Ž¨Ü4*ÏEŒj·øÉÜûKZVâ\³®‘óé‘<k‡5 Nñ§õ'(-’I¯t¤~/¿ÛUÚ$È½Õò…$Ú¡Spòá¼Ê£A(î«×» ”=O™Ãð&m_õƒVP¼®L£À·OÙì†®Ó H¯5æUrgôf¼H/ïÇåÐ®`K3Jäà4ägt«v)w–^¨>[{Ø[Vˆý%ÕU|ãÈÎà&ˆ á¹`´ó„ÖÄT¥Ç¸J ãY",ƒ`?Q·±Ö¹z•p@PÐeh*0ƒ¹–6±¾ÂPTÍ7"c‚É`Ï…Œ(¼Nm©F)“‡ì‡ó-“»âûÒ»$H¯¯³ƒãà1#˜eqI9oÔ›xInø6ðõc|H?žóEÇ4h«˜Ê¬" xn¨¸ ¤ ,?a(j-AÂ°C,ú¬”`œøé²Â1×ÒÌ5“-Í,ÛLçåa&<[ †Z†Öv°§Z¥ÞÆÒuPµ|£¡“ìäêÑ2MÆÊål(ê³J§§Ê˜üN‰0–:‚¿À|YØš^"fCå¬œEkä´FƒEà¹YX§ ³QÒHÄ¹¢Ê6à2ÖUDE2 u (ÈÎBËò4×ÜÌµÍÈ³º°$½•ÿ’9/AÓe4¨!æ'ÌP"m{*àúA#ŸW@ñw³–aÃ‹‰¬«cÙ:”Ç|2—žËI[^.Ž8x9ð4œ ÷Ëˆð¡öÈ±¸)³¤)¯D_œW ©()Í=L~vhÿ*–†Ëm²5©I‰©Â¡ò˜0Ò?°éxGÝá¶Rú¸ñº«„H˜Îô#ÒöÇîIß›! ?Wëâ£è¡`< Ù$&™M‘”kºÚ°È¶#ê^ÒÔ–SÕH?|ëmn»{UŠæ÷¯à³>{TÔWêm6Í§/¿w¿{Ùëpò¦m¶nö-U”h‰e:¸Lôæ+h¤ÊU:“¡¡i) :elM)Â¢#ÝI8Îùð f.\Ì-º@ó¥9¥¥R€ÙÞ€ÖhÔº7èKä%'ê“ÈðàTEí¼S†¦xm‘úâÃöx3ƒí¸ŠE=;]Àz>‰º¸cä±.–mÿ-ZÐÆãù'áälì.ó¥ºuÂAª8™-åQ×]§ecf¹g‰7¸#EáI{)Ã|¥Ó?Q6³ƒ¯vÂÒS5IIReu|¯šzÝ‹‰Ë”+¥‹îí@CÚªGÀúÇð›)øº@áÉwV7KKi6?IÆ¾Š¦^º«¾þð)i¥¶2ã e¿˜Øáãåäèvä³«-'®}Ôì`OÍê$Vn9üÉg5èèÜ#m9&` aN+×n‚£hÑ±ÏOÂöÝö¿°Ûl¯_ÁÁ»/¼xý¨÷r qÆÕ˜Ñ(Ý`~\\~¿ZëŠk÷+ðÿ8M\4µÎcÀ—‚ßäˆf'K ‘ž”¸3ÎI# ïÀ«Š´y´>ƒ–KaôS†ÆÃò!¡ŒP)•¦³¹Þd6«ê•ÈÊQ°øg+ÎÈJû/|‚ÏToH §”I‘ÉIdrÇ§ÑÅØ…î¶®fº¥Çxõ:ø+Âlª7›#LJ¥*B©¬W™i‘ùû_’ø+[G”Û/‰¡ppæ~Ó€Õà Y}U '‚ ÑÕÑÕ±µ@|×TÛ^×ÍHgâ~~»vïñ±w[<ñß#îÏM·ÿµ"üé9ÍèßßÍƒ+æ›)¸éikçÉÍO&QZëñ«µ~ø÷[ÏÚùG§ÐšMØÕð}õÎ¤¿JCotDµ÷Gi#:Ö‚kÄ¿“w1'ÿïºz¤¡çëŸÐÇ¤Yá$¸dî48R÷f‰¹t±Åøæ"‰yÀI€þáë–O~DªùKèðëè(† æ‡1ˆàÆßì„Ç6÷e7‘&“¾¨‚‚[XKÕ©‡è’7ûÎK>²´¤j¥=ÆÜûC€G…9…úBª©¢ëÈ-ò‡ãkçBlãr[²Þ@”ó–)¿rÊyÄ©þ?qÊ’†wçž¯ì¤ânaX•·{±©Td¤'ÒË\±Ý!¾;gHgõ¿fgP•lµ®¬ðû«âS6‘ÛöíÏ«‡`Â½—{û3BÛ(¤þ<ñOŒü#ŠKz‚’µøåÞ¾ÞöªèHU%(c°¼Œ}!KUFÒ®(Üßý!¢©Ý`:áÁº§yS‰Çgö“H¹Ž:F½¿«>g¤×”„Ö–¶–½{ö¼b/Õ€&7®C×., ð1xsçB«Šþxº?þ´ºW-lÊ¨ˆK]]ƒ¶9¯¯¹Duã¢û–‰ìÆmDž¬jã©þ“)XFrœ:‚ôM©é£A˜„ž‚S4X'Þ£?“×K¥ÔòÄ`µD§â""¤ðU!X.ºaÉù³vºwß¾yëü„žÛèÿÃòv¸mÎ"ðR{I]uíÄ¨Å!9`þ£²ìÿM”6V´ÕñM¼¸»ÃÈ°‘±;ïfY^©Ú(ñ})Î#Ú#ÆSŸÝ =ùÃ¿aã1´> x.oe*Ù¼ø¼d X;4”¶uVtEà pl'RUjUŠj0‹ÕíC+ß5bÑ? þÃÃB8ÞÀÔ1eÉ¦e’Gð3ì¨à>ˆ/ï¨DgHÀ‹ðÖ'¨y£òZý¥ë`¸î\y} o9"TÎ„"}Ê# ;ìDcˆIô–ì‡S“|üý$‡ÓLi¦t³$J JÝ ŸÓ€-VXPÌ—’¥ +p>stream hÞ´Xy|Seº•“Ñ¨èÑäœûË‡;ƒà‚à‚‚€@EŠ,….@÷&MÒ´ mÒìÛI³oMÒtIº¤¤´M7Z(… ²ƒ‚ èè\G®ËŒ:~éœÎ½÷—ùáuÔùãþòßù’ó>ïó>ïó¾_fÐfÆÑfÌ˜qç+ëV\µæ±•y•›ž}ùéÅÓÏX1ü¶{É¥dèïºIrîw—ý?°â9Óg³~ú"mõ¡ÝG»+Ž†ÆÑpí„öØLÚS4ÚÓ·Ð–Òh«´D„–Ä ñh´g¨`´™4:íê|‰ö—«f4ÇÝÇ«¿…}KÇ-±™\ä¤“G?ÿdüu†ekÖÈÜê½löÄm+o;|û}·2ç2ß±ëÎ¸;…wNÝµmÎ‚9îwGïyèç=“hàÞûïýø>)kËÁ®%'©ïÎ½~^+Z›žäP²º½¯_:z9úG¶Êûd)Â,j„"6ÑŽ!d#9"p&Z(*ÜUÔ,oé F#mUA`Âã“Ñ‡–ÏÏÙó%$cFÎê"ï†àÛs—¿ä~å‡·_ÁàÌ8‹D9‹þ±}BöÑ[g]W½gÁµ@LtüKûC«’älþýà~úã+q&ü:öjïu÷9{¥Ö£9É[åI5lÅ&‡îÚÀÞúžº.{ÉT‹&S#.Ö³ŸQê„ˆyâhí>q¤–˜¶¶ÕVd‡EáîÁ|Ö 5ÄaBÚ)Ôè€ZèGFô]zû&áøÃ;2jxùœämAr²gpÿ)üâ@æËË¶.Hß?9ï…gÕñæógkÏãçÏÔçAà¼Ö‰h‹³tù8ÓOÑÃ…öxñÃªL™Šg`/¹âèxíQüèX-q”B±ØˆÍ›k1ý×r‰Þ Œ þˆÞ†÷Ð?ˆmQÛÖJÙjÔJ¼JþB¦Ñ Â„ñð}4ÒÑÓqÿ¤wósl#™düÂŒcŸúA¹M½]¹MQÈÎÝTqÿó_Û‚ûê‡bß%œ|(s³¤¸„C˜G¡1ôõ}øè¨Ù2 ºi]‘œL¤âIIVKPëÖ“_S‘ð¿Ñw#IkžË'o}teÑ¹ôCÚ—fÃQ«´ÚT?˜úÂ:ðìÃÛI6ÉÆì¹Þ~õ“3oD9-ÃžáQì“ÌSVmÚžœCEõž]ë»À¾Ð71v6©ÀiB˜s¿ù%ñƒ_þðPF=ìýQQÿˆåLnC§fMý)sH'Ö±wëÒxS4jêÁ{zŒÆÐŸbA¤&‰Ó¹Ýú0ç¯ðeéä&Ä¤´È˜´FYJp2 ˆ Þ40`êÇúÆê‡B‹ÈRmÕ;Ø:—ÞOøO"¬×æ¢fz”ìEH. k?Ÿ\€ŽíF—ÒXÅ6JbMÞâ)K/â„:]ËÔ6uà‘N£1öût{í×gý2±oV¶<íæ˜ã¯µ|vñsJõ‚ëcêv" OÛn6¥ª¾E?¤x^ðÐüu/’q…EVK6ø[ìohÐÔli21.[‹aäÓä¤PpNÆ>‹Õ£í³Ùë¨ó ÿ£uÃºú<õ ÅkOráƒ"ò¹™ôÝ\˜týZûÄ{wÒìX¾YðN.]IõìpÝûpÜ~úœ<0cO}tN¥òF*‘ˆ)‚Ÿ¥Á¤†{L'®^!®î‰š÷âf¯Ékr[ö¸Çœƒ]²Q‘«’åØúÌL"ÏÎ±X3§¶îÎèýýÃÜÛiîø%8•ÿ„“õœ£7ÃY1µ–¥HÔV«Õ:ÒPe,4°ôÄÔ;dÆ‡†ÆƒÀÒ¾Þ‚pMººzŒ¢ÈìátÁ<ä— bAl’2C§#j´°,aÄÈÍ!²ñlª"[¨àþœk).Þa‘4IqF^#¯µª€Eˆh]^½¿4qùó0p†míÖ0ƒRŒPïuô:~û½ÓIúYR9ß'µïÇ¤º¨¤¶SI™už“ *ÿ YÔÉèÌb›B!SÆèÇ—‹ëÚ*i„Gà0lCê¼ÍÞ&¼¹n,¯ Êñòr³©”Æ+ÊË¥RyyoZjJÖÎöt•\ÿî%ÿZ~S9À178'Üû\zõy†B&Øê]Ë?ÓFìÝÉÏ&g£æ¦€»ÝÔk¾•/ ø8Ÿo6ñ …ŸÌK%SKYäüØÛ7ømD'qÈ ÙÊ&ž²×¤UI“ulC2íhQ¼÷†£YÚó-ˆÀ\áòaufŸ-ÀwÄ²3Î›z Ñ¯Ã_ÀU_Ã—F?`™‰‚)¡¨ÄXb`s ªûoÔ`ŸÑ8L½§À‚[Ä”°êj=¦ ùSP9ù j.˜M ãw~cƒÎ«f{4¡2-¦2È9çé©R½H#T+Ù•Ü !¸–NðÊ(…2 líÙ‘YbÑyÙ:_mƒµåJ,‡EüdêMd”þYì çœ·Ûê`[õ–:SÔÌ²Q4•æyxnÞ4:ª8H«Ñ£Æ†J¢†óÂT5BL›.œ ïBM^£Tj¯Þ,¯÷ckÈ´…ØÖPÐÚ‚9^øÀSžW.rÔq™‹Ôt„T{qÈþÞïƒ³^Œ>Dcz:‘NM@³iU™#?s³é®ø-$¿ ôBâìn«mÆß>\ôâcK™tƒ®'ÃÍÜÀ®FÛš‚xj h‹Ï²Êü¢2†Yõ~÷>ŒÃ¾YYDpŒiiÓó"ÕlJû¿ÞBAL‰¥ÄºÐ=të!ç>ï#”»Ó“Ž“w’÷/ ±E{w~R®—#ã²öâ$lÞªõóSÒ=Ùœ/yñº4uŠ"QÑVº‡÷Ãù_Á~µóÅxÕ‡¼â+žÇ>¹xü£Á!ù®öi×Ža“z‰>~L§¶‹ÖBÅ×¯g…éíð9ÄøÄBb!¾pÙ´T‘Ï!tÿëÖ€=àô°ö¶0gÒ—L5(5ìï‰LýžÈ±‰¢ˆÜt3‘”Z'Sr»žï»[ðcw'QtŒÜìv‰SsX/'?¾n!¾*aïûÔµ6cBÄÈ+%JqÏlâR?:L -F·AŒ© B}9gýÔlÄ 6TŠ12þòÎ¿]‡ñÞšà˜ MŽ*W™Ã¶éSëÓ¼£czÆÛÚ7Z‘Ym÷bíöÖƒâ$¼{r*—U«,"–#PosáûÛò š@dó›$O»«’œs“[îø>÷Ñ_Q\èv‡¿¹¡Gª+ê€Ûêy£Î Û)-°UáJ¡“ƒé’µ ¹Z¥V©Äª*]¹–'}‘UZÃ—•*u¬«t=7q å.b<É-0íÆËk|~¨ÑU’Z[ooÔ»ñÞÖpôG»'Z¯¶<•¡o)|˜£#ã¾¦!°¿ùÀþqlˆÛC™ÖÆ¤¼AlÃ¨9Üœ!¼ëD1á!¼œCØÔnu ³vDYÄ5â#• nÎÏTgnI¹¥^Æž8WtÕI9A^!"—K©ÕÉ\Î3"ò–´±Ç!üÒ`)u•fa¯<&HÞðBûÛ×Þ¾à\Œ%¡ç‚¹kV—Ì{vUÅá‹ŸŽŸ>O]g“¿¡“lRVI2rÈÂel‡ò‚ß9áûªÿ"ûêð×Ÿâ¦¦J·K™RÉTD[¡á‰°2wM³¿Éåòszš»Zû:” ,a5"-Jå¸FëòÔY¼V?8 ]ˆ½ÍÖÚ‚´ Â¢å‰ œ]\a¿HofQ.‰=‡yô |\V¡[;ðÅq¸ñ·Ô{=¸×&Sªô»õ°ŽÔü[a/Æ¤hgpO³$ æ ŠxŸ¤ Pf%ûMvÍb’Î#i%ä}l—ê\}Þé:Øv 3ÂnNÀ>Ê;¿0—'—p9$-)…Œ'1±ô±ççË³å°ùú¢èŠÝ§°¿³åÂá‡ó°¿Þú+µ®5¼òÚ29;³Ü¨¬*“ó±è&´¥>Ö³úòÛ¹óžF¿¥ßcÍ¨³Ý”IÒ·¯ØÜÑsdÐÊ˜´Ö*Ÿ•åÿ±©•69¾9iI6lÕŽ 'ÔŠ·^Ä+…Z©l~. D‚ímAü°ÿÁ";ðlÈÝ€ð«vLïä2³Ãa„©%Ð-ª¼ƒø¥cGÇÁÈ‰Ž³-áý±D–ÂU®¨E»z]Õ:irñjn{KÞÎüÝxµ.²Çü0s=Š&1.SèŠRÁóIžª‘Äîv9œx£µ¤ˆÕ¤1V×VK0¡¯8Ò1zhO'ÒÕmí5¬ä3ÊâÝ‰Âdö6AaF2žËÛ{È ”V„y¥y¦Sˆ„ÂÝÎv|x¸F9´{:µ{pŸ×joÞÎW”QA¯Ø¨*ÛÙècÛ…éîœ[¢‘©© ?Ž1í*Wy9¢T¨õR>stream HIBACH+AdvPSMP10ø‹ûÂúqù¶ÍÔ‹÷Ø AdvPSMP10CF‡ô÷áø¼÷™ø‡•º ßµµ——£•ž§»}Eboû=g{}`Œh®“œ™¸kœVX/Yû+3mi›·gûûE†v€]yh×š«“ªŽœ¯÷D]´²±è÷è÷.Ìn½=»ö³¸×ÑÚK»:Ufypo]]l1„iø÷‡ø^)WQQY¨k¸u7^VG[±J÷÷¾Ð³ ‚uZ’=jj‡‡x|lE€¾©¶Ã–Ž©£«ˆ“žŒ›‘ˆ•{xmnez¡¶¸¨ÞËªžvnh”p¨¢–¡´^¼? endstream endobj 73 0 obj <>stream hÞTU TW¦»~u6XìÒª&*DiE‹Ø²©*‘M0€ÝÐ**‹ÝÀ£$QZ’€Ë¨,’ Ñ¸…ˆG£2.ÑI F1HbÂÅ¨Ì«ž×äL5sfÎÌ©sþ¯ÿªÞ{ÿ¾{ßÿ2JáDÉd²WæÅD„‡‡OÏ.ŽŸ©sØÆŠœLë¢Fæýsm fWhtÛ6Öy½;å$“UÕGæ”˜sV¬,Ô¾‘5I;58(Ð×1¾92;Æ`6<;ßhÒ&”X M¹mL^V¾¹ ßl(4eOÑjÃ×¬ÑŽD°hÍ&‹É\,Yç™Ö› s²Ú‹Ö -4²M¹ójmþrm\N^~aII>WkÈËöÏ7ks$_K‘Ñ’“c0ç˜,Sþ‹’IÅPÔ(ŠrUP,EyÈ©×)j¢œò¡(? ‚)*BAÍ§¨r*AN¥Ê(© ”Br{—ÚE5PÇ©™B#Ë•m“Ùœ:-sªt:çô½ÓSù|yŠ|¹|¯ü²‚Q*¬ŠÇ4EûÑqôz9ÃPÌhÆ“Éf>´Ú¾eÅ¡ÊàñCÏ€½ûb-ºú ã¤.Ôp¸ÞS1R_‰®à4^XÑt%\¹Ç?Ÿ¼Þ"ìB'ŽÆë#B·YŸ‘4þïWÑÐk§¤¥ÂV¡¶‘gp™ý9]NÐ >§Q6ö‹3ÉžòGíš ö'ôoÒ$Jõ˜W®+ÖØg2ªÍbð¬ä‚b7ŒÃ¥»‚ˆ2{7 2›ÑOÂd{Å0?t•T£óWƒ°~iÒ®_2†ñƒjðîÁ=ÁhAô¿fØ{îƒüyU"ÄÚ\YH%?|›§ó‰_=]À$¤€bºË@‚2´ÇØ5‚n3,€V6PVÍ‰/¨DYM¦/ï&¹ueµ6oµ‡uÐø‰±Nyºñâñ! ø¢ó tæñG‡»ÍUeäì½÷Qî9»$JÀ"‘âVö®Õ>¸…ÃˆtBº :S*€w ÎùÇ,³5Ð¹$ÚßóKI:2¯jQk"Ÿwø|¶Ô¶Øi§aèKS4œ¡ ;—Õ·j@ö¬®õÞ/+Q¾•Wikl.,X‡]l.`íµÿ AOILÙÓÔy§M÷= :^\âc·0¨é‘øN‚Ô_¤ØÞ¼¸œ‘ªÔ7ÄŽ'ÒH¨•tüLš²–9@hE›àJ‚óñÎ‡4ªlÂg¸Ó® á%Ká,$áY\$aŒ)¶y[Më ×Óœ›˜bþ ¸\À‰%4z•¬Ÿ˜©™z}Ño¿_8Ót”Ïª¬Êþž«¯ÞVY+\eÊß+-ÿ€+)ÝÑ ÀE4è[e@6( Ý¬Ú˜2ˆã8“Ô7'?D'ð¿s ìÙ!Ì ¡ë–dÆs8ªä?ÿzì9Èî7DïT¢UªxÖ’òôçÅYßør(ÌD‚ÞèvC`Î¹+µ7¿*"{ˆý%i×¶cáÕ7…éË&gO0úU“P¾8ó`/ƒvÝ~]Ñýà«CM¼téi¯ð 4° Û†£0GA4HÜ.h©© ÆT|°uÀÑŸ‚8‹ö&l?"ùÊÖ§s–’[J…PÆZ³ÓZÍ½£ Vô×@ô WúH,µŒ¶™Ø 06” endstream endobj 58 0 obj <> endobj 74 0 obj <>stream hÞw?î]L/y7foÜ;‚²H|¸©¸I°è¸8ÂZ"²(¦Íªä¤5”á”Ã”°Ì‚Š Â”QS ±™Ê§"",È 6jcˆ’Öhïnï2ÓåOsþ½çyÏó>Ïó†¨„a˜°ª9ÙlŽJ¶ç´¯³å³¾4ÎÖ°÷òˆ²õµ‹ö÷{«Ô²Ôÿ¿¼¬:4µ÷å÷?Ž0ò!|W b2ëyª‚8"»vÇsl¨§˜ÄB¾/B€é‹`˜Ì¾¶¨––s=Ç/Ÿ"ó[®ãJ OÌØYÞw´“jn¸©{¤îù¤n*B_“Ú-I‡M"–É˜¡Ù–±½}%6Ó§¿AN¯‹üý£²¥½™%é".ceŸ’µ^ûš;Ç{b`ƒ ÎYüfÆ©«Ã—Ç+¥‡.ê¬Óàº“Î+²fuïn¿9TßÝ!9wUæž9¨q;Zv\ü¢®²ümå² ?jÕAs—ŸÕ£:6ùbé û êò÷÷Ä ×[é…Ž÷ŠiAñÎÏ÷94<4…üÜO€€=jJ¨-K2Gˆ¨N›‚@Š‰ªrvMÓí]nLƒ0¢!ÜÆ›“ßY·ƒÂiëŒ½WŽ´Áó®ü¦E¡:"é:hË$Ðìy"0î…èGÁ¬ºº#ùG³(÷¢€á=ˆsÀä¾íj¢å±½^»U‹6aºº{ô¹¤;!‚öÛHwŸ¢^ÄEq€Q=‚~°‚ûnLŸ¢öõÂôm+Eä¬ rR>ÂdK³–B04.g}u£tñdgÛ qêô–W(Ž÷ÂC®¹ìç¼Ÿ¤®o|µNLÙ’›µ™ŽX}µ³J~øD€ðI °¯„y¸&äeÞT ñì ° ¾PiC‚AÈ¥?Tÿ@¼Øf@Þ)ñ¥ B¥×K¥Î˜ýÞòÝÔñx–@–˜ÒK…ÈÃÃ‰À‹ÀuþIa3Ž.0ÝÅ³®_oví5UÉ™ß~sªda–´W)nƒÑçhÐÙÞÎ1Æå4Ž}$É»SÙ*”}\Z$Ú_wR€ÇX`ÅfÛuŸ?—Ø˜÷KýwÇ*j$Þc‚²ëEÛÛÇ$˜°â#IKHãçÚ] RJ¯§Ö*kOyèÉ|¹½žÜéŽÈ~®µ¼³¯ê„£´ZºÄU9EÓžM 4á5çYæËä&_-wÕkRãÝò¯hŸ·„ÿnÙ Ò endstream endobj 59 0 obj <> endobj 75 0 obj <>stream HIBACF+AdvP7C31øû%û˜ú|ùbÌÑ‹÷W AdvP7C31"w÷Žù–øi÷b¸û˜k€u{ŠVˆgŒÍ½Œ²²¼ŠŠÎ¯sŽl~š€¤û—øñD|b{bqFûIüJnyoqˆmˆgŒ»¯Œ¨¨¯ŠŠ»¯YŽyŒw™±µ÷÷÷Êóû’û` endstream endobj 65 0 obj <> endobj 76 0 obj <>stream hÞ\“pSUÇ_Ò¼¼ŒS‚O4—}÷‚ºE»—n-¥h-ZmÇÆ¦Í#M“4)ÝR“Ò4í{½/mC…b6m¨”VCþäÇ*@ î.?Vpd,£®ÎŽã¬»37z;;ûÒå{çüqæÜïùœWEiÔ”J¥Z²5ÿwÙ9y«²µÛŸÎÍÊÊÌJy—'*¹<ý!²ŽôüÒù³‹Æ ‹p÷]ËµCK(µJÕÏq{ê½v[e ÿdÅ¯ùŒ Ïf®NÙ¬»!e7¬[°|¶Õ].ðEõ¾ÁåãówU¸½·×R#XŸâùl§“_Ðññ^Á'xkïv‹ÓRcßåæí>ÞÂ¶Á-³ÕÁeñ:³æ÷NþeÅ]³§ïøì<Þ²ËºÖíåíÊSßîrŸÝj·xí‚ï©ÿ)…R)‡ºŸ¢rTÔŠÚJQÛ(ª@C¥Q(åSŠ¡ž º©Û*¿ê[õ õž4:.mLcÐìÕÜ¦WÑ-ógôä¼rq^ÄVœ{s0ÓºÉœs0ðð‰÷gnž¿=ôÍ#z\ŠÃ¬¼ÿ€Ü¾>%ä•º·®³¾’å¹ó˜\§‘ûzä>ði²ú÷+¹ñ¨´Ú<ö•¿¹{›AÃí±Ñ é$Àê¹s8íbÑ™§”™]cÓŸfwæŠLb 0 í²º™KÑ+Ô‹ÉþŠ?~wš;dÊz¯déZ²‰¬ÄºGñúï®Çú?€þ½óy€<¶åGÌ`pëËÝ9árÄaGÇ:L±/¶øŸç<šAãSÓâ˜œFáQØq<<Îèªµ¡ª «É£úÌ!3°{dÙÛ&¥+_Po/êw÷ù_†h¥#ÒðQCEqÎ¥-jM„j¸i6|–G…c`jª-xvÕ¢Ú° ;¢•§:]ÃºNGi¸ØvŠ¢ Š6›¸Tºeä„æf´5?Ujþ‰b-ý^qa4-DC–1`†0xÝÅ?½¿ Å¸¤´+~Ž1Ò;µ’Û^!¿|Ì%±7Teð´ÛE/ç¯w7¿ Jˆá(.Âé3ßãÅ"¼$ÝÚ6‡ëI5Nÿ[ØÌN5cbM€ñ1IƒqfCsäÄ³Ì{Ñ î#½^)A‰YF6eWbb1Ôcõ?ÙüÆs0õx$ŽNNŠcƒáÉÎ“Ý§t.mÝst“»¨µ¸ëªƒmCR|Ø€£ÌÅÃèò‚n©h&›ŒLŠî^É¤èÖ%ï°øµä&Z&ßj+üÜT†Écè4˜•¤„‚÷R}÷T ïÒáð…”ŒCPd|J}°lÅŽŒds/â'wt’Ë)º€½JF©Uº<°×É,S¸;”·À=‚†ÁG IúHQÍ«(ª‘üÚüeU4X7Ç¾¹'ðB*røC4÷"ÛÔyâóJäõùe_4ÑâPë±Q>Åü¹7ò×`à°Ê¨°À±õúé¸¿È¤$™³æ±õÃK°ÂâG³Ù’Ç)³Õ‡O¹óÈÏÄUéÐ°÷‡A³å±õ†X²’<˜A6“g0·§ãþ…^ô¬#›áÛv/>ûY¼ÊE´ä>Â[ðCX—|vmNivŽ5ÕïÉ¹7Îqp}D’b)Þÿþ žg:ûÞ€SBaË’ë÷‡;›a—‹níîkœþÉí«ŸÙÏP]-Š^(z} cù2r+Œ_î–(«ÙÿÓöË“0©eöEcòapmx×¶B“¹°1€P¶6à·HˆÆ‹ûµÎæ}±:HÖàBz*:ûÎp'¿=Wüj[‰±<\îé“«Ìöz1‡ÓóøßIŠM È‡ÜÝÂáÍ€Ï*|îÇ™dáùGÁÆª£79·¶Hª Ur ##Y€Ùo>ÿb$kq†áãS‰ËÇÿ®§©«uÊÿWøÇ'þ“'$é„ÂŸÛ¸&Õ§™»Ý~A†r}DÛ—ÑmÆœvBBå´‡°ƒ,Süò(»ÜgçÕZcC0—SfVœÌbì¿,sŒôªCtK™ŒÊ”–Í„v@òCîOlÅÏáƒßÿÄas®'r-µ$ÕU¢TÚþû©nEö¾‰“YYj}f…ãÜ§O¶=˜<ÃþG€;êË endstream endobj 66 0 obj <> endobj 77 0 obj <>stream hÞbd`ad`ddððtrtñÐvL)®Ì‰‰ýæûíú{û¯ó¿ÚXÏð_ìþ^,’á„+F†nfFF&ÖÉ|ßûø~®þqð‡†hÛÒæÕ+Cw(õFY¸vÿ¶<æ|Áò;÷Ì‡vïéY×3Ÿ#†3¿º°¸4!Ñ~rêv¿ËK¿ó®Úxæîw¸ÉÎbE×ûû=õ¾ƒéßz@‘` ÔÂ`¹Íbßm¾Ë¡ ˆþ-ûÛá4H\Ž Àß‹bM endstream endobj 72 0 obj <> endobj 71 0 obj <>stream hÞTP=¯Â0Üó+<‚Ò²!U•OOêÀ‡(°‡Äí‹DÈM‡þ{’R@oðI>ûtgË]õS‘ OìtK†±wk„;¶– _ƒ±:ÌÝ„ºSd×c°«¨qPBžã°<Ââw³Ê– l-µ°¸ä×[$êÁûvH2(K0Ø¹Û+P‚L²/w=ÂzêóÙØì½ÒÈŠZ„B©òHæÿì¸7úO±xmfÙv[Š¸;³I•NùÐsÌ6Ý;EHæ–ðóï|òJ%ž Ji” endstream endobj 70 0 obj <> endobj 78 0 obj <> endobj xref 0 79 0000000000 65535 f 0000000650 00000 n 0000000015 00000 n 0000000377 00000 n 0000001467 00000 n 0000000105 00000 n 0000000922 00000 n 0000002016 00000 n 0000001195 00000 n 0000002290 00000 n 0000001741 00000 n 0000002563 00000 n 0000006003 00000 n 0000006080 00000 n 0000006190 00000 n 0000006267 00000 n 0000006377 00000 n 0000006454 00000 n 0000006564 00000 n 0000039891 00000 n 0000006994 00000 n 0000043448 00000 n 0000041577 00000 n 0000041960 00000 n 0000046138 00000 n 0000048489 00000 n 0000038289 00000 n 0000006880 00000 n 0000023065 00000 n 0000023518 00000 n 0000037428 00000 n 0000038938 00000 n 0000023393 00000 n 0000035994 00000 n 0000036302 00000 n 0000036522 00000 n 0000036805 00000 n 0000036868 00000 n 0000036916 00000 n 0000037594 00000 n 0000039830 00000 n 0000039866 00000 n 0000040039 00000 n 0000039958 00000 n 0000043550 00000 n 0000044382 00000 n 0000045268 00000 n 0000047586 00000 n 0000048863 00000 n 0000049689 00000 n 0000050695 00000 n 0000051559 00000 n 0000040618 00000 n 0000041027 00000 n 0000046754 00000 n 0000050531 00000 n 0000046908 00000 n 0000040454 00000 n 0000068854 00000 n 0000070418 00000 n 0000042640 00000 n 0000042952 00000 n 0000052152 00000 n 0000054459 00000 n 0000047239 00000 n 0000070942 00000 n 0000072831 00000 n 0000060517 00000 n 0000048653 00000 n 0000065949 00000 n 0000073866 00000 n 0000073583 00000 n 0000073362 00000 n 0000066338 00000 n 0000069199 00000 n 0000070682 00000 n 0000071153 00000 n 0000073075 00000 n 0000073930 00000 n trailer <<5955d59cb02884f2b796dea0cf0394b7>]/Info 78 0 R/Size 79>> startxref 74262 %%EOF